

Dobyns William (Orcid ID: 0000-0002-7681-2844)
Siegel Dawn (Orcid ID: 0000-0002-8209-122X)
Stevenson David (Orcid ID: 0000-0001-8601-0020)
Rauen Katherine (Orcid ID: 0000-0003-1719-7228)

GRIPP ET AL

Costello Syndrome: Clinical Phenotype, Genotype, and Management Guidelines

Karen W. Gripp^{1*}, Lindsey A. Morse², Marni Axelrad³, Kathryn C. Chatfield⁴, Aaron Chidekel⁵, William Dobyns⁶, Daniel Doyle⁷, Bronwyn Kerr⁸, Angela E. Lin⁹, David D. Schwartz³, Barbara J. Sibbles¹⁰, Dawn Siegel¹¹, Suma P. Shankar¹², David A. Stevenson¹³, Mihir M. Thacker¹⁴, K. Nicole Weaver¹⁵, Sue M. White¹⁶, Katherine A. Rauen^{12*}

¹Division of Medical Genetics, Department of Pediatrics, A.I. duPont Hospital for Children, Wilmington, Delaware

²Ferre Institute, Binghamton, New York

³Psychology Section, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

⁴Section of Cardiology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado

⁵Division of Pulmonology, Department of Pediatrics, A.I. duPont Hospital for Children, Wilmington, Delaware

⁶Division of Medical Genetics, Seattle Children's Hospital, Seattle, Washington

⁷Division of Endocrinology, A.I. duPont Hospital for Children, Wilmington, Delaware

⁸Manchester Center for Genomic Medicine, University of Manchester, Manchester, UK

⁹Medical Genetics Unit, Department of Pediatrics, MassGeneral Hospital for Children, Boston, Massachusetts

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/ajmg.a.61270](https://doi.org/10.1002/ajmg.a.61270)

GRIPP ET AL

¹⁰Division of Pediatrics, Erasmus MC- Sophia Children's Hospital, Rotterdam, Netherlands

¹¹Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin

¹²Division of Genomic Medicine, Department of Pediatrics, University of California Davis, Sacramento, California

¹³Division of Medical Genetic, Department of Pediatrics, Stanford University, Palo Alto, California

¹⁴Department of Orthopedic Surgery, Nemours-Alfred I. duPont Hospital for Children, Wilmington, Delaware

¹⁵Division of Human Genetics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

¹⁶Victorian Clinical Genetics Services, Royal Children's Hospital, Victoria, Australia

Running Title: Costello Syndrome Management Guidelines

Corresponding Authors

Karen W. Gripp, MD, FAAP, FACMG
A.I. duPont Hospital for Children
1600 Rockland Rd
Wilmington, DE, 19803
Phone: (302) 651-5916
Email: KGripp@nemours.org

Katherine A. Rauen, MD, PhD
UC Davis MIND Institute
2825 50th Street, Room #2284
Sacramento, CA, 95817
Phone: (916) 703-0204
Email: rauen@ucdavis.edu

ABSTRACT

Costello syndrome (CS) is a RASopathy caused by activating germline mutations in *HRAS*. Due to ubiquitous *HRAS* gene expression, CS affects multiple organ systems and individuals are predisposed to cancer. Individuals with CS may have distinctive craniofacial features, cardiac anomalies, growth and developmental delays, as well as dermatological, orthopedic, ocular, and neurological issues; however, considerable overlap with other RASopathies exists. Medical evaluation requires an understanding of the multifaceted phenotype. Subspecialists may have limited experience in caring for these individuals because of the rarity of CS. Furthermore, the phenotypic presentation may vary with the underlying genotype. These guidelines were developed by an interdisciplinary team of experts in order to encourage timely health care practices and provide medical management guidelines for the primary and specialty care provider, as well as for the families and affected individuals across their lifespan. These guidelines are based on expert opinion and do not represent evidence-based guidelines due to the lack of data for this rare condition.

KEYWORDS: Costello syndrome, HRAS mutation, management guidelines, RAS/MAPK, RASopathy

INTRODUCTION

An apparently novel neurodevelopmental syndrome having distinctive craniofacial features, high birth weight with subsequent failure to thrive, and ectodermal anomalies including nasal papilloma was reported in two unrelated children in 1971 and 1977 (Costello, 1971; Costello, 1977). The eponym, Costello syndrome (CS; MIM 214080), was applied after a third patient with consistent clinical features was noted to have a similar phenotype (Der Kaloustian et al., 1991). The prevalence is estimated at approximately 1/300,000 live births (Goriely & Wilkie, 2012; Abe et al., 2012).

CS is one of the RASopathies which are a group of medical genetic syndromes caused by germline genetic mutations in components and regulators of the RAS/Mitogen-Activated Protein Kinase (MAPK) pathway (Rauen, 2013; Tidyman & Rauen, 2016a). The RAS/MAPK pathway is a well-studied signal transduction pathway with the RAS protein being a small guanosine triphosphate hydrolase, or GTPase, acting as an on-off signaling hub inside the cell. RAS proteins consist of a large family of GTPases of which KRAS, NRAS, and HRAS are the most commonly studied because they are frequently mutated in cancer. The RAS protein has numerous downstream pathway effectors of which the MAPK pathway is the best studied due to its role in tumorigenesis. The RAS/MAPK pathway has essential cellular functions including cell cycle progression, differentiation, transcription, proliferation, apoptosis, and motility. Because of the important nature of RAS in cellular function, perturbing the pathway during development has multisystem consequences (Rauen, 2007). The RASopathies have germline derived dysregulation of this pathway and include neurofibromatosis type 1 (NF1), Noonan syndrome (NS), Noonan syndrome with multiple lentigines (NSML, formerly called LEOPARD syndrome), Noonan syndrome with loose anagen hair (NS-LAH), cardio-facio-cutaneous syndrome (CFC), capillary malformation-arteriovenous malformation syndrome (CM-AVM), Legius syndrome, and SYNGAP1-

related intellectual disability (Tidyman & Rauen, 2016b). Although individually each syndrome may be rare, together the RASopathies represent a common group of neurodevelopmental syndromes affecting more than 1 in 1000 individuals. CS affects multiple organ systems and shows phenotypic overlap with other RASopathies. For these reasons, an international panel of CS experts was convened to create management guidelines for health care professionals. The overarching goal of these guidelines is to assist in the clinical and molecular diagnoses, as well as the medical management of CS individuals across their lifespan by providing the most current medical and scientific information for families and medical providers. These guidelines were developed by expert opinion and do not represent evidence-based guidelines due to the lack of data for this rare condition.

MOLECULAR GENETICS

Costello syndrome is caused by specific heterozygous activating mutations in *HRAS*, a highly conserved gene located on 11p15.5 and encoding the Harvey rat sarcoma viral oncogene homologue, HRAS (Aoki et al., 2005). While somatically acquired *HRAS* mutations are associated with sporadic tumors, CS is typically the result of heterozygous, de novo germline mutations in *HRAS* (Estep et al., 2006; Gripp et al., 2006a; Kerr et al., 2006; van Steensel et al., 2006). *HRAS* mutations associated with CS result in a gain-of-function which causes constitutive activation of the RAS protein (Aoki et al., 2005) or more complex dysregulation (Gripp et al., 2015; Gripp et al., 2017) of the RAS/MAPK pathway.

Most *HRAS* mutations are paternally derived and associated with advanced paternal age (Aoki et al., 2005; Estep et al., 2006; Sol-Church et al., 2006; Zampino et al., 2007; Giannoulatou et al., 2013). The identification of a known CS-associated germline *HRAS* mutation confirms the diagnosis of CS and may clarify the diagnosis in individuals whose phenotype overlaps with other RASopathies. For novel

variants, a careful review and validation is necessary (Grant et al., 2018). Molecular confirmation of the clinical diagnosis assists in clarifying risks based upon genotype-phenotype correlations (Table I). This implies that adults clinically diagnosed with CS prior to the identification of causative *HRAS* mutations should now be tested. Failure to identify an *HRAS* mutation is most commonly due to the individual being affected by a different syndrome, typically another RASopathy (Table II). However, somatic mosaicism should be considered in individuals with clinical features consistent with CS or individuals with a milder presentation of phenotypic features involving only limited organ systems (Gripp et al., 2006b; Sol-Church et al., 2009; Gripp et al., 2017). Given that the majority of individuals with CS have a *de novo* mutation, the risk to siblings is low; however, affected siblings have been reported (Gripp et al., 2011a) and gonadal mosaicism in a parent was confirmed in one family (Gripp et al., 2011a).

MUTATIONS AND GENOTYPE-PHENOTYPE CORRELATIONS

Although data are limited given the rarity of CS, some genotype-phenotype correlations have been reported (Table III). More than 95% of CS-causing *HRAS* gene mutations involve the amino acid glycine at position 12 or 13 in *HRAS* (Sol-Church & Gripp, 2009). Glycine 12 and 13 are important for GTP-binding, affecting the activation of the RAS/MAPK signaling cascade (van Steensel et al., 2006). Approximately 80% of mutations result in a p.G12S missense change and as a result, this mutation is associated with the classic CS phenotype (Figure 1). p.G12A is the second most common missense mutation reported in CS. This mutation may have a higher rate of malignancy and individuals may have a more severe phenotype (Figure 2). A severe neonatal phenotype has been reported with p.G12D, p.G12C, and p.G12E missense mutations resulting in severe cardiomyopathy, pleural and pericardial effusion, and lung abnormalities (Lo et al., 2008; Weaver et al., 2014; Kerr et al., 2006). The p.G12V missense

mutation is associated with severe cardiomyopathy and tachycardia, as well as respiratory distress resulting in early death (Aoki et al., 2005; Sol-Church & Gripp, 2009; Quezada & Gripp, 2007). Detailed functional studies based on an unusual patient with a non-lethal phenotype due to a c.35_36GC>TG mutation (p.G12V) demonstrated the effect of alternative splicing on the phenotypic presentation (Hartung et al., 2017). The p.G13C mutation may be associated with a milder phenotype characterized by taller stature, absence of ulnar wrist deviation and a lower risk for malignant tumors or papillomata (Figure 2; Sol-Church & Gripp, 2009; Gripp et al., 2011b).

Among the less common mutations, HRAS p.E63_D69dup causes an attenuated phenotype with milder intellectual disability, fewer feeding issues, and a lower tumor risk (Lorenz et al., 2013; Xu et al., 2015). Facial features tend to be less coarse in individuals with the rarer HRAS missense mutations p.T58I, p.K117R, p.A146V and p.A146P (Kerr et al., 2006; Gripp et al., 2008; Chiu et al., 2016). HRAS p.A146T has been associated with a milder presentation resulting in minor skin and joint involvement and milder growth restriction. HRAS p.G60D is associated with an overall milder phenotype and parental transmission (Gripp et al., 2015), whereas the only individual reported with HRAS p.G60V died in infancy (Gripp et al., 2017).

PRENATAL FINDINGS

A prenatal diagnosis of CS should be considered in fetuses with increased nuchal translucency (including cystic hygroma), polyhydramnios, ulnar deviation of the wrists, hypertrophic cardiomyopathy, or fetal tachycardia (Quezada et al., 2007; Van den Bosch et al., 2002; Smith et al., 2009; Lin et al., 2009). Polyhydramnios is present in more than 70% and may be related to reduced fetal swallowing (Van den Bosch et al., 2002; Smith et al., 2009; Lin et al., 2009; Myers et al., 2014). Fetuses with CS tend to be

large for gestational age which contrasts the failure to thrive and growth delays seen postnatally (Quezada et al., 2007; Van den Bosch et al., 2002; Smith et al., 2009; Lin et al., 2009). Fetal tachyarrhythmia is fairly specific to CS (Myers et al., 2014). Preterm labor is common, as is the need for early delivery due to complications from fetal overgrowth, polyhydramnios, or fetal distress (Smith et al., 2009; Lin et al., 2009; Piccione et al., 2009). Ultrasound findings may include macrocephaly, ventriculomegaly, shortened long bones and pyelectasis. Many fetal characteristics and prenatal ultrasound findings overlap with CFC or NS, emphasizing the importance of molecular testing.

CARDIOVASCULAR DISEASE

Cardiovascular disease is present in 85% of individuals including hypertrophic cardiomyopathy (HCM), congenital heart defects (CHD), dysrhythmias and/or hypertension. Cardiovascular disease is the major contributor to morbidity and mortality in the first years of life (Gelb et al., 2015; Lin et al., 2011). HCM occurs in approximately 60%, accounting for 75% of cardiovascular pathology (Lin et al., 2011). Hypertrophy can be asymmetric/septal or concentric, with left ventricular or biventricular involvement (Lin et al., 2011). The clinical course varies from a rare severe neonatal lethal form, to the typical mild to moderate form of HCM seen in the majority (Burkitt-Wright et al., 2012; Lorenz et al., 2012). While long-term natural history data remain to be collected, follow-up of 146 patients ranging in age from one month to 40 years (with only 13 individuals >18 years) indicates that many had chronic or progressive hypertrophy (37%), a quarter had stable disease, and a fraction (14%) had improvement or even resolution (Lin et al., 2011).

A CHD is identified in 45% of individuals (Lin et al., 2011). Pulmonary valve stenosis (PVS) is the most frequent CHD (15-20%) and may be accompanied by subvalvar and supralvalvar pulmonary

stenosis, and double-chambered right ventricle. In most patients with PVS, the mild-moderate obstruction requires no intervention. Atrial septal defects (ASD) are uncommon (5-7%). Other infrequent defects include ventricular septal defect, mitral valve abnormalities, aortic thickening or stenosis, bicuspid aortic valve, coarctation of the aorta, patent ductus arteriosus, and aortic root dilation. Coronary artery anomalies have been reported in autopsy specimens, characterized as premature coronary disease, and coronary fibromuscular dysplasia (Kerr et al., 2006; Lin et al., 2011).

Atrial arrhythmias are very common in CS, seen in over 50%, and are typically characterized as non-reentrant atrial tachycardias (NRAT), ectopic atrial tachycardia, multifocal or chaotic atrial tachycardia (Lin et al., 2011; Levin et al., 2018). Non-reentrant atrial tachycardias are often diagnosed in the first year of life and are stable or resolve in 70%. Later-onset atrial arrhythmias, namely atrial fibrillation and flutter, have been reported, whereas, ventricular arrhythmias appear to be rare.

Because of the high prevalence of cardiovascular disease, urgent pediatric cardiology consultation is indicated upon diagnosis of CS. The evaluation includes echocardiography (ECHO), electrocardiography (ECG), and continuous telemetry or Holter monitoring. HCM and NRATs are most likely to present in infancy, so frequent surveillance in the first two years of life is appropriate. Reevaluation in early childhood is dictated by abnormalities, with intervals determined by age in the absence of cardiovascular disease (Table I). Treatment of HCM includes medical therapies to reduce heart rate and outflow obstruction as per published guidelines (Gersh et al., 2011). Severe outflow obstruction has been treated with septal myectomy. Conventional antiarrhythmic treatment of NRATs by a pediatric electrophysiologist is effective in most patients (Bradley et al., 2001; Salerno et al., 2004). Surgical correction of CHDs is rarely necessary. Little is known about whether HCM and other myocardial disease can develop at older ages. All individuals with CS, even those who have had previous normal ECHO or

underwent surgical repair of CHD as young children, should have periodic cardiac reevaluation by a cardiologist. Hypertension (Estep et al., 2006; Lin et al., 2011) and sudden death (presumed cardiac) is not uncommon (Lin et al., 2011). Given the risk for acquired and progressive cardiovascular abnormalities, screening for HCM with ECHO and ECG, early coronary disease, lipidopathy and hypertension is warranted throughout life (Gersh et al., 2011). Short and long-term outcomes of surgery in CS are not described, but higher surgical mortality related to comorbidities must be considered.

NEUROLOGIC FINDINGS

Neurologic findings are common and include structural and functional abnormalities. Structural central nervous system findings include absolute or relative macrocephaly, ventricular dilatation, crowding in the posterior fossa that may be severe enough to meet criteria for Chiari 1 malformation, and rarely Dandy-Walker malformation (Delrue et al., 2003; Gripp & Lin, 2006; Gripp et al., 2010; Gripp & Lin 2012). While these findings may be present in early infancy, they can progress. Crowding in the posterior fossa is at least partially attributable to bony posterior fossa hypoplasia despite normal hindbrain volume (Calandrelli et al., 2015). A combination of typical infantile brain growth and possibly *HRAS* mutation driven overgrowth with decreased cerebellar fossa size and altered cranial shape predisposes to cerebellar tonsillar herniation that when severe presents as Chiari 1 malformation (Paquin et al., 2009; Calandrelli et al., 2015). Crowding in the posterior fossa and cerebellar tonsillar herniation through the foramen magnum can impede cerebellar spinal fluid flow, contributing to enlarged ventricles and syringomyelia formation. Syringomyelia may result in peripheral nervous system symptoms such as weakness, pain or abnormal sensation. Tethered cord is more common than reflected in the literature and should be suspected in all individuals (Gripp et al., 2010). It is currently unclear if progressive Chiari I

malformation, syringomyelia, or tethered cord and their neurologic consequences contribute to the development of scoliosis, developmental hip dysplasia, tight calcaneal tendons, and hand or foot positional abnormalities. Seizures occur with increased incidence (Kerr et al., 2006) and are treated as in the general population. No particular type or age of onset for seizures predominates. Due to the risk for hyperinsulinemic hypoglycemia in young infants (Gripp et al., 2015) or growth hormone deficiency related hypoglycemia in older individuals (Gripp et al., 2000), new onset seizures should prompt an evaluation for hypoglycemia.

Neurologic management in CS is life-long and referral to Neurology is important at diagnosis (Table I). Serial clinical exams need to focus on gait abnormalities including toe-walking, tendon reflexes, and other signs of slowly progressive cord disease. When Chiari I malformation or syringomyelia is symptomatic or shows significant progression on imaging studies, neurosurgical consultation is indicated. This often leads to posterior fossa decompression, and sometimes repeat decompression (Gripp et al., 2010). For concerns of tethered cord, lower spine imaging at diagnosis or by age 1 year is indicated. Because tethered cord can be difficult to identify with certainty on imaging studies, a high index of suspicion should remain and symptomatic individuals should be re-imaged. Preliminary data suggest that many individuals with CS may have 6 lumbar vertebra and, therefore, it is important to count the vertebral level from the cervical spine down to appropriately ascertain the level of the conus.

NEUROCOGNITIVE FUNCTION

Intellectual disability occurs in approximately 80% of individuals with CS (Axelrad et al., 2009; Axelrad et al., 2011; Cesarini et al., 2009). The majority fall in the mild to moderate range, with roughly

one in five showing more severe impairment, and one in 10 showing low average-to-average performance. Nonverbal fluid reasoning is a relative strength, with about 20% of individuals falling in the low average range, whereas verbal reasoning and visual-spatial skills are areas of relative weakness. Preliminary evidence suggests that individuals with the p.G13C missense mutation have better cognitive and adaptive functioning (Axelrad et al., 2009; Axelrad et al., 2011; Gripp et al., 2011a).

Most individuals with CS show speech/language delay, with first words generally occurring between the first and second year of life (Gripp et al., 2011a). Speech onset often coincides with resolution of early feeding problems and toleration of oral feeds (Gripp & Lin, 2012). Speech/motor impairment persists (White et al., 2005), although a majority of individuals are able to speak in full sentences by adulthood (Hopkins et al., 2010) and some individuals successfully learn sign language (White et al., 2005). Standardized assessments reveal overall language abilities in the mild to moderate range of disability (Axelrad et al., 2009; Schwartz et al., 2013), though functional language comprehension may be better in familiar environments. Expressive language is typically worse than language comprehension, likely due to speech and/or articulation difficulties. Vocabulary development may accelerate slightly in adolescence or early adulthood.

Neuropsychological assessment of attention is challenging, as participants have had difficulty understanding task directions. Parent report indicates attention problems in approximately one-third of individuals with CS (Alfieri et al., 2014), though attention is probably commensurate with overall development. Verbal recall memory is generally in the mild to moderate range of disability (Axelrad et al., 2009; Dileone et al., 2010; Schwartz et al., 2013). In contrast, verbal recognition memory appears largely spared, falling in the low-average to average range (Schwartz et al., 2013). Memory for narrative information is better developed than memory for less structured information, such as word lists. Visual-

spatial memory ranges from mild to severe disability (Axelrad et al., 2007; Axelrad et al., 2009; Dileone et al., 2010). Visual-motor abilities appear to be a relative weakness. Fine-motor deficits characterize most individuals and are compounded by positional hand anomalies and movement limitations.

Academic abilities are generally at an early grade-school level. Based on standardized testing, most individuals attain basic word reading and spelling skills between a kindergarten to 2nd grade level, while a few progress to a 4th-6th grade level. Math calculation skills generally fall at a kindergarten to 3rd grade level. Reading comprehension and applied math problem-solving skills tend to be less well developed (Schwartz et al., 2013).

Adaptive behavior is generally commensurate with intellectual functioning. Social skills tend to be better developed, whereas practical daily living skills tend to be weaker, in part due to orthopedic disability. Females tend to have better social and communication skills, and moderately better daily living skills. Most individuals with CS attain a limited degree of independence as adults, being able to feed, clean, and dress themselves with minimal help (White et al., 2005), and more than half can search the internet on their own; however, most are unable to complete more complex tasks such as managing money (Hopkins et al., 2010).

Most individuals with CS require specialized programming in school, typically in a life skills placement (Table I). Children in the U.S. should be given a comprehensive Individualized Education Plan. Learning may be facilitated by embedding content in narrative formats, and knowledge may be best assessed using multiple-choice formats, which are preferred to more open-ended questions. Children should be referred for speech/language evaluation to make recommendations for speech therapy, and for assistive technology evaluation to determine whether an assistive communication device might prove helpful. Use of an assistive communication device or Picture Exchange Communication System helps

children with developmental disabilities communicate (Ganz et al., 2012). Children with more severe speech problems can be taught sign language. For motor deficits, individuals should be referred for occupational and physical therapy and, in school, an orientation and mobility evaluation should also be completed.

SOCIAL, EMOTIONAL, AND BEHAVIORAL FUNCTION

Infants and toddlers with CS have been described as characteristically withdrawn, irritable, and hypersensitive to touch, which may be associated with underlying feeding and medical complications (Kawame et al., 2003; Galera et al., 2006; Gripp et al., 2010). Early feeding difficulties and irritability both decrease over time (White et al., 2005). Many children younger than age 4 years also show elevated symptoms of autism-spectrum disorder (Adviento et al., 2014), though it is unclear if older children may emerge out of an autistic-like presentation (Schwartz et al., 2017; Young et al., 2018). In later childhood and adolescence, social skills emerge as a relative strength, especially among females. Individuals have a distinct personality profile as they age, including agreeableness and sense of humor (Bizaoui et al., 2018) and are often described as sociable and friendly (Gripp & Lin, 2012).

Individuals with CS experience elevated rates of internalizing problems, including separation anxiety and school anxiety (Kawame et al., 2003; Galera et al., 2006; Axelrad et al., 2011). These symptoms tend to be most prevalent in males and persons with lower cognitive ability, suggesting that they find school stressful. Anxiety should be assessed in school-aged children. Children may respond well to family-based intervention for anxiety with an emphasis on exposure therapy. Parents may also benefit from support as having a medically complex child can be stressful.

About half of individuals show mild behavior problems such as temper tantrums and disobedience (Axelrad et al., 2009), although compared to normative samples, relatively few behavior problems are reported (Alfieri et al., 2014; Axelrad et al., 2004). In CS adults, parents reported quality of life is inversely related to medical issues (Hopkins et al., 2010).

ENDOCRINOLOGIC FINDINGS

Endocrinopathies common in CS include neonatal hyperinsulinism, hypoglycemia, growth hormone (GH) deficiency, and problems with puberty. Neonates and infants are at high risk for hypoglycemia and should be screened immediately after birth and during ongoing medical care in the first year. Blood sugar levels less than 70 mg/dl should be addressed according to the Pediatric Endocrine Society recommendations (Thornton et al., 2015) and blood sugar equal to or less than 50 mg/dl should have a diagnostic sample (glucose, GH, insulin, cortisol, beta-hydroxybutyrate) obtained at that time to define the etiology of low blood sugar to guide management. Neonatal hyperinsulinism (Alexander et al., 2005; Sheffield et al., 2015), GH deficiency (Stein et al., 2004; Gregersen et al., 2004), and late dumping syndrome due to gastrostomy and fundoplication can cause or contribute to hypoglycemia (Calabria et al., 2011) with each requiring specific medical management. Infants or young individuals often present with low serum glucose due to GH deficiency and symptoms may include syncope or seizures. The incidence of GH deficiency as defined by an abnormal growth hormone stimulation test result may be as high as 30% (Estep et al., 2006; Gripp et al., 2010; unpublished data).

Delayed or dysregulated puberty may be due to the relationship between body fat stores and initiation of pubertal development. Individuals with CS typically have low body fat mass and delayed puberty (White et al., 2005). Current pediatric endocrine society guidelines dictate that females without

development of secondary sex characteristics by age 14 and males without the development of secondary sex characteristics by age 15 should be evaluated for causes of hypogonadism, such as gonadotropin deficiency or gonadal failure. Precocious puberty has also been described (Kerr et al., 2006). Its etiology should be differentiated between an early rise in the central signal for puberty (early gonadotropin rise) or autonomous function of a sex steroid producing gonadal or other tumor. Different hormone producing tumors such as focal hyperinsulinism (Gripp et al., 2016; Dickson et al., 2004) and parathyroid adenoma (Cakir et al., 2004) have occurred.

Evaluation for GH deficiency includes measurement of insulin growth factor (IGF) levels followed by a GH stimulation test (Table I). Once a diagnosis of GH deficiency is obtained, but before treatment with GH is begun, a thorough cardiac evaluation should be completed. Patients should be monitored every 6 months for the first year of GH replacement for development of hypertrophic cardiomyopathy. Individuals treated with GH should follow existing guidelines for surveillance for rhabdomyosarcoma (Gripp et al., 2002) since growth hormone is a mitogen which may affect the growth rate of neoplastic cells. The goal of GH replacement is the prevention of hypoglycemic episodes and the anecdotally reported increase in muscle tone and strength, rather than increased height growth. No systematically obtained outcome data are available to document the benefit of GH replacement.

Management for early life hyperinsulinism may include diazoxide with close monitoring for cardiac status. Appropriate management for pubertal issues depends on the patient's height and bone age and the initiation of sex steroid replacement may be postponed to augment final height. Bone mineral density must be investigated in patients with delayed puberty and, if low, may be treated with calcium, vitamin D, sex steroid replacement or bisphosphonates. Gonadotropin-releasing hormone agonists may be used for central causes of precocious puberty and tumors may require excision.

GASTROENTEROLOGIC FINDINGS

Severe feeding problems and failure to thrive are almost universal in young children with CS. Feeding difficulties include suck and swallowing dysfunction, severe gastroesophageal reflux and oral aversion. Weak suck and swallow dysfunction originate from the fetal period and continue into childhood. Contributing factors are macroglossia and oral hypersensitivity. Gastroesophageal reflux disease (GERD) with extensive vomiting, irritability, and disrupted sleep is a frequent and disabling issue (Kawame et al., 2003; Leoni et al., 2016). The combination of GERD and swallowing difficulties contribute to lack of weight gain and respiratory complications like choking and aspiration pneumonia. Oral aversion can be triggered by negative stimuli like choking, vomiting, nasogastric tube placement, and sensory integration difficulties. Poor general condition with cardiac and pulmonary manifestations of CS as well as generalized hypotonia can contribute to poor oral intake (Digilio et al., 2008; Lo et al., 2008; Myers et al., 2014). Pyloric stenosis is relatively common (5/58 in Gripp et al., 2008; 1/3 in Digilio et al., 2008) and should be considered in infants aged 2 to 4 months with progressive vomiting. Individuals can display gastrointestinal motility disorder with intestinal pseudo-obstruction and chronic constipation.

Despite extensive therapy and supplemental feeding, infants can have a characteristic appearance of malnutrition which can disguise distinctive dysmorphic features, thus eluding the clinical recognition of the syndrome (Zampino et al., 2007; Chiu et al., 2016). Generally, feeding difficulties diminish over time and most children take oral feeds between age two and four years. Remarkably, the first acceptable tastes are often spicy and strong (Gripp & Lin, 2006). Most teenagers and adults eat independently (White et al., 2005; Hopkins et al., 2009; Abe et al., 2012). In individuals with the HRAS p.G13C mutation, feeding problems may be milder and of limited duration (Gripp et al., 2011a).

The treatment of feeding difficulties is complex and requires a multidisciplinary team consisting of a pediatrician, gastroenterologist, dietitian and feeding therapist (Table I). Conservative measures like positioning, hypoallergenic or thickened formula, blended diet, and frequent or continuous feedings have limited success. Treatment with proton pump inhibitors may be of value. Prokinetic agents should be considered if gastrointestinal motility disorder is suspected. However, these drugs may have important adverse effects which may lead to arrhythmia. Swallow studies, including flexible endoscopy, and additional gastrointestinal imaging is often indicated in the evaluation and management of dysphagia, gastroesophageal reflux, and pulmonary aspiration. Most infants require a nasogastric tube or percutaneous gastrostomy (Leoni et al., 2016). Placement of gastroduodenal or gastrojejunal tube, jejunostomy, or fundoplication may be necessary due to severe reflux or impaired gastric motility (Lightdale et al., 2013). Adult-onset GERD may be related to Chiari malformation (White et al., 2005; Hopkins et al., 2010). Because vomiting is a recognized Chiari malformation symptom, GERD in older individuals also merits neurological evaluation and possibly a brain MRI. Individuals with CS have an increased resting energy expenditure (Leoni et al., 2016) measured by indirect calorimetry, likely reflecting an increased cellular basal metabolism and contributing to failure to thrive despite normal to high daily caloric intake (Leoni et al., 2016). Normative growth charts for CS individuals receiving medical care have been published (Sammon et al., 2012).

RESPIRATORY AND OTOLARYNGOLOGIC FINDINGS

Complex pulmonary and airway co-morbidities are present in a significant proportion of neonates and infants with CS (Myers et al., 2014; Gomez-Ospina et al., 2016), and are more common and severe than in the general population, even accounting for prematurity. Upper and lower airway abnormalities as

well as abnormalities of the lung parenchyma such as chronic lung disease occur. In infancy and early childhood, redundant nasal tissue, relative macroglossia, laryngomalacia, hypopharyngeal wall collapse, or nonspecific airway obstruction can require an epiglottoplasty or tracheostomy placement. Anecdotally, mucus production is increased and may compound respiratory problems due to hypotonia and swallowing dysfunction limiting mucus clearance from the airway. Chiari I malformation can result in dysphagia and central sleep apnea. Tracheobronchomalacia, chronic lung disease of infancy, and frequent respiratory tract infections tend to improve with age related growth and development. Other problems may arise, including adenoid and tonsillar hypertrophy. Nasal papillomata are common in older individuals and may require removal. Obstructive or central sleep apnea (Della Marca et al., 2006), ongoing parenchymal lung injury, or the evolution of cardiopulmonary disease require early recognition and treatment (Gomez-Ospina et al., 2016).

The pulmonary evaluation and management is individualized, but common tests may include chest and airway imaging, flexible (dynamic) and rigid (static) laryngoscopy and bronchoscopy, and polysomnography (Table I). Chest and airway imaging can provide an evaluation of the lung parenchyma and evaluate for airway narrowing or tracheobronchomalacia. Airway endoscopy will confirm the presence or absence of a specific fixed airway lesion such as subglottic stenosis, or a dynamic airway upper or lower airway problem such as airway malacia. Polysomnography will assess control of breathing and confirm the presence or absence of sleep disordered breathing. Additional imaging may include CT scanning to provide a more detailed assessment of lung parenchyma and with IV contrast, a more detailed assessment of pulmonary blood flow. Assistance with anesthesia planning is an important role of the pulmonary consultant. A collaborative, multidisciplinary approach is preferred and involves the expertise and skills of a pulmonologist and otolaryngologist. Evaluation of potential cardiopulmonary interactions,

particularly in patients with congenital heart disease, and ensuring a safe and efficacious feeding and nutritional plan may require input from cardiology, gastroenterology, speech therapy, and nutrition specialists.

DENTAL AND ORAL FINDINGS

Dental and oral issues in CS are perhaps the most severe of all RASopathies. Individuals with CS have oral habits including a secondary tongue thrust, open mouth posture, and excessive teeth grinding/bruxism, resulting in an anterior open bite with a posterior crossbite (Goodwin et al., 2014a). Individuals have a significantly increased incidence of class III malocclusion (37%) whereby the maxillary first molar is positioned posteriorly to the mandibular first molar (Goodwin et al., 2014a). The majority have a narrow, high-arched palate with thickening of the posterior maxillary and the anterior mandibular alveolar ridge. Malocclusion and palate issues can contribute to obstructive sleep apnea. Gingival hypertrophy is common (Hart et al., 2002). Most (93%) have delayed dental development with delayed eruption. They typically do not show increased dental crowding, hypodontia, supernumerary teeth, or abnormal tooth morphology. Microdontia has rarely been reported (Takahashi and Ohashi, 2013). Nearly all individuals with CS have an enamel defect characterized by demineralized white focal and striation lesions allowing pathologic wear due to increased susceptibility to abrasion and caries (Goodwin et al., 2014a; Goodwin et al., 2014b).

Medical management includes regular dental exams with a general or pediatric dentist (Table I). It is not uncommon for CS individuals to require anesthesia for dental visits. Special attention to oral hygiene is important since gingival hyperplasia makes cleaning difficult and enamel hypoplasia increases susceptibility to caries. Increased fluoride treatment can decrease caries. For bruxism, a custom mouth

guard may be considered. Anticipatory guidance should include the possibility of delayed tooth development and eruption. Early referral to an orthodontist is recommended, especially for class III malocclusion.

MUSCULOSKELETAL FINDINGS

Musculoskeletal findings are common and include scoliosis, pectus anomalies, osteopenia/osteoporosis, hip dysplasia/subluxation, vertical talus, tight Achilles tendons, large and small joint contractures, ulnar deviation of the wrists, hypotonia, joint laxity, and muscle weakness (Yassir et al., 2003; Detweiler et al., 2013; Reinker et al., 2011; Stevenson & Yang, 2011). Decreased bone mineral density has been reported in multiple RASopathies and is common in CS (Leoni et al., 2014; Stevenson et al., 2011; White et al., 2005; Detweiler et al., 2013). Osteopenia may be present and individuals may be symptomatic (White et al., 2005). However, the resultant impact of fractures due to osteoporosis in CS has not been well elucidated. Vitamin D deficiency has been documented in European groups (Leoni et al., 2014).

Scoliosis, as well as kyphosis, has been reported in 17-63% of individuals with CS (Yassir et al., 2003; Detweiler et al., 2013; Reinker et al., 2011; Stevenson and Yang, 2011). Scoliosis can be severe and progressive. Pectus abnormalities are frequent (6-30%), but rarely require intervention (Yassir et al., 2003; Detweiler et al., 2013). Reversal of the normal sagittal profile of the spine with thoracic lordosis and lumbar kyphosis may be seen (Detweiler et al., 2013).

Hip dysplasia affects 17-45% and may be seen early in infancy or during childhood and adolescence (Detweiler et al., 2013; Yassir et al., 2003). It is hypothesized that early on, hip dysplasia is usually bilateral and likely a result of hypotonia and ligamentous laxity. Hip dysplasia may be identified

at routine screening and should prompt a referral to orthopedics. Late dysplasia of the hip during childhood/adolescence is almost always unilateral and is a poorly understood phenomenon in CS (Detweiler et al., 2013). These individuals may present with worsening of gait, hip pain or a limb-length discrepancy. Surgical reconstruction is often needed and can be challenging. Hip flexion contractures can be observed without concomitant hip dysplasia (Detweiler et al., 2013; Yassir et al., 2003).

Limbs are often described as thin and lacking musculature. Abnormalities on muscle biopsies suggest an underlying myopathy (van der Burgt et al., 2007; Tidyman et al., 2011) with in vitro biochemical studies demonstrating that CS mutations dysregulate skeletal myogenesis, providing further evidence that individuals with CS have an intrinsic myopathy (Tidyman et al., 2011). Almost three-quarters have Achilles tendon contractures which usually manifest as toe walking (Yassir et al., 2003; Detweiler et al., 2013). Congenital vertical talus (17-28% of individuals) is noted at or soon after birth. Other foot deformities such as talipes equinovarus (2%) or pes planus (53%) occur. Progressive unilateral foot abnormalities, especially in childhood, may indicate a tethered cord and should be investigated appropriately. Shoulder and elbow contractures occur in 65% and 55% of individuals, respectively (Detweiler et al., 2013). In addition to elbow flexion contractures, ulnar deviation at the wrist (63%) may be present. Radial head subluxation or dislocation at the elbow may occur. The wrist-hand deformities are characteristic and include short, broad hyperextensible digits as well as ulnar deviation. Hand grip weakness is common and may, in part, be due to the positioning of the hand and wrist, although intrinsic muscle weakness has been reported in other RASopathies (Stevenson et al., 2012).

Referral to orthopedics and physical therapy for, at minimum, baseline evaluation is indicated for all individuals with CS (Table I). Radiographs are diagnostic for hip dysplasia and in such cases referral to orthopedics is indicated as there is a high likelihood of needing surgical intervention. At each physician

visit, individuals should be evaluated for scoliosis with the Adam's forward bend test (Adams, 1865).

Referral to orthopedics as needed for the appropriate management for scoliosis. In general, rapid progression of scoliosis may be seen in individuals with central nervous system involvement. Given that central nervous system findings such as Chiari I malformation, syringomyelia and tethered cord are common, MRI of the entire spine should be considered in individuals with scoliosis, particularly with rapid progression.

If fractures occur, dual energy x-ray absorptiometry (DEXA) should be considered, but the small stature of CS individuals needs to be considered when interpreting the results. Vitamin D supplementation may be needed to maintain sufficient serum 25-hydroxyvitamin D concentration. The orthopedist will be helpful for evaluation of the frequent joint abnormalities. Treatment for Achilles tendon tightness is often a combination of physical therapy and splinting, although botulism toxin injections have been tried anecdotally. Surgery may be required if it is refractory to these therapies. Recurrence of Achilles tendon tightness may be seen and may necessitate repeat surgery. For joint contractures, encouraging proper posture and stretching, as well as overhead activities may be beneficial. Occupational and physical therapy may be needed for stretching and bracing at an early age.

GENITOURINARY FINDINGS

Prenatally, renal anomalies are present in up to 83% of fetuses with CS and include echogenic kidneys as well as dilated renal pelvis and pyelectasis (Myers et al., 2014; Lorenz et al., 2012).

Documented postnatal renal anomalies include echogenic kidneys, ectopic kidney(s), enlarged kidneys, dilated renal pelvis/pyelectasis/hydronephrosis, and renal collecting system anomalies (Lorenz et al., 2012; Lo et al., 2008; Digilio et al., 2008; Lin et al., 2009; Gripp et al., 2012; Dickson et al., 2004).

Kidney stones may occur in children and adults (Sol-Church et al., 2009; Gripp et al., 2006b; Assadi et al., 1999) and a bladder stone has been documented (Assadi et al., 1999). Additional genitourinary anomalies include cryptorchidism, as observed in other RASopathies, hydrocele, inguinal hernia, hypoplastic labia or prominent labia minora (Gripp et al., 2011a; Digilio et al., 2008; Hennekam, 2003; Smith et al., 2009; Cakir et al., 2004), and anecdotal reports of bladder diverticula. Bladder papillomata and transitional cell carcinoma of the bladder may arise from late childhood to adulthood, for screening recommendations see Hematology/Oncology section. Renal ultrasound should be considered at diagnosis with appropriate follow-up with urology as needed (Table I).

OPHTHALMOLOGIC FINDINGS

The majority of individuals with CS have eye findings and vision problems with strabismus, nystagmus, and refractive errors such as myopia, hyperopia, and astigmatism (Estep et al., 2006; Gripp et al., 2006a). In a cross-sectional study the majority needed corrective lenses for refractive errors, myopia being most common (Shankar & Rauen, 2009). More than 50% had strabismus, lack of depth perception, and reduced visual acuity. Photophobia with avoidance of bright sun light was reported in a number of individuals. Ptosis is common with many having compensatory head posturing. Numerous individuals undergo strabismus correction surgery in early infancy or early childhood, with exotropia being more common. Nystagmus has been present in individuals without optic nerve or retinal problems and may diminish with age. Amblyopia is a common finding (Shankar & Rauen, 2009). Two individuals had keratoconus (Costello, 1996; Gripp et al., 2013). Posterior segment findings include optic nerve changes ranging from hypoplastic optic disks to small but normal appearing optic disks, tilted and irregular optic disk margins, and peripapillary pigmentation and atrophy. Retinal dystrophy occurred in two individuals

(Pierpont et al., 2017). The management of ocular issues in CS is life long and should begin early to prevent vision loss and amblyopia (Table I). Refractive errors and some strabismus are managed by corrective lenses, and, ptosis and strabismus may need surgery. When optic nerve problems are noted, brain MRI is recommended and unexplained decreased vision may require electroretinogram to evaluate for retinal dystrophy. Pediatric ophthalmologic assessments should begin at birth or at the time of diagnosis and continue every six 6 month for the first two years of life than annually or as recommended by an ophthalmologist.

HEMATOLOGIC and ONCOLOGIC FINDINGS

Children and adults with CS have an increased risk of malignancy, predominantly for embryonal rhabdomyosarcoma in early childhood, bladder cancer in adolescence and early adult life, and neuroblastoma (Kerr et al., 1998; Franceschini et al., 1999; Flores-Nava et al., 2000; Sigaudy et al., 2000; Moroni et al., 2000; Gripp et al., 2002; Urakami et al., 2002). From a review of 268 published cases, the cumulative risk for cancer by age 20 was 15% (Kratz et al., 2011). Rhabdomyosarcoma had been reported in 19 patients (7%), bladder carcinoma in 4 (1%), and neuroblastoma in 5 (1%). The maximal risk for embryonal rhabdomyosarcoma occurs until age 6 years (Gripp et al., 2002) and the majority of tumors arise in the abdomen or pelvis (Robbins et al., 2016). The high childhood malignancy risk has been confirmed in a population-based study in children up to age 14 in Germany which demonstrated a standardized incidence ratio of 42.4 (5.1-153.2; Kratz et al., 2011).

It has not been firmly determined at this time if the malignancy risk varies with the underlying mutation. Given that 80% of individuals with CS have HRAS p.G12S, this missense mutation predominates also in patients with malignancy. In addition to malignancies, a number of benign lesions

have been reported including ganglioneuroblastoma, a calcified epithelioma of the neck and epithelial paratubal cysts, acoustic neuroma, and stomach polyp (Zampino et al., 1993; Martin and Jones, 1991; Suri and Garrett, 1998; Di Rocco et al., 2003). In adults, breast fibroadenomatosis, intraductal papilloma, a parathyroid papilloma and choroid plexus papilloma have been reported (White et al., 2005).

As expected for such a rare disorder, there is no evidence on which to base a screening protocol, in terms of effect on mortality and morbidity. Based on literature recommendations, physical examination plus abdominal and pelvic ultrasounds are suggested every three months until age 8 to 10 years, and annual urinalysis from age 10 (Table I; Gripp et al., 2002; Villani et al., 2017). Screening for neuroblastoma has been complicated by the demonstration of abnormal urinary catecholamines in the absence of neuroblastoma in patients with CS; as a result, this is no longer recommended (Bowron et al., 2005). Although the malignancies with a very high relative risk in CS have been well defined as outlined above, it remains unclear if there is an increased risk of other malignancies, but with a lower relative risk, as seen in NF1 (Narrod et al., 1991).

DERMATOLOGIC FINDINGS

The dermatologic features in CS are distinctive and several are unique to CS. The vast majority of individuals with CS have curly hair (95.7%) with frontotemporal alopecia (30.4%; Siegel et al., 2012). The hair tends to be sparse, brittle and slow growing. In contrast, the fingernails and toenails grow quickly. The nails tend to be brittle and thin. The full, thick eyebrows are a common feature (47.8%) distinguishing CS from individuals with CFC who have thin, sparse eyebrows. Loose anagen hair syndrome has been reported in a subset of individuals with HRAS p.G13C (Gripp et al., 2011a) and some had very long eyelashes which required regular trimming.

Papillomas often begin to develop on the nasal ala and anterior nares, appearing from infancy through early adulthood, occurring in 71.7% of individuals. Other locations include the face, ear lobules and perineal region. The papillomas tend to be soft, flesh colored and small, often only 3-4 mm in size (Siegel et al., 2012). Hyperkeratosis develops in pressure areas on the palms and soles. This palmoplantar keratoderma becomes significant and symptomatic through the teen years in approximately three-quarters of patients. The palms and soles are notable for deep creases with loose, wrinkled or redundant skin. It is common for patients to have a darker skin color compared to family members. The majority experience heat intolerance, excessive sweating and unusual body odor (Siegel et al., 2012; Morice-Picard et al., 2013). There are a few reported cases of severe generalized cutis laxa in the infantile period which improved with time (Girisha et al., 2010). Acanthosis nigricans, thick, hyperpigmented, velvety skin on the dorsal neck, axilla and less frequently dorsal hands has been reported in approximately one third. The age at presentation of acanthosis nigricans can range from early childhood through adolescence.

Regular evaluation by a pediatric dermatologist is important to monitor dermatologic findings, primarily papillomas and palmoplantar keratoderma, which may require treatment (Table I). The facial papillomas and palmoplantar keratoderma can have a negative impact on quality of life due to stigmatization, pain, and functional impairment. There are no FDA approved treatments for the papillomas or palmoplantar keratoderma. Treatments that have been used for papillomas include snip excision, cryotherapy, cautery and imiquimod cream; however, these generally provide only temporary benefit and the lesions frequently recur. Palmoplantar keratoderma is managed with topical tazarotene, urea cream and physical paring. One case report described improvement of acanthosis nigricans after treatment with isotretinoin for nodulocystic acne (Sriboonnark et al., 2015).

Individuals with CS have a high rate of sensitive skin and eczematous dermatitis. This can cause itching and discomfort. Eczema should be managed with sensitive skin care. The use of fragrance-free products (including soap, moisturizer and laundry detergent) is beneficial to preventing skin irritation. Thick moisturizing creams and ointments are more effective as emollients than lotions. In some cases, prescription topical steroids are needed. Sun protection, including the use of hats, sun protective clothing, sunglasses and sun screen, is important. Sun screen should be reapplied every 2 hours while outside, especially if swimming or sweating.

ISSUES IN ADULTHOOD

There is very little literature describing the health concerns specific to adults with CS. Two studies describe health concerns in 22 adults (16 years and older) with CS (White et al., 2005; Abe et al. 2012). Of these, 15 (68%) had cardiovascular pathology, eight individuals had isolated cardiomyopathy, five individuals had cardiomyopathy and arrhythmia, one individual had mitral valve prolapse and regurgitation, and one individual had pulmonic and tricuspid valve regurgitation. When comparing this group of 22 individuals to a cross sectional cohort of individuals with CS of all ages (61 individuals, mean age 12 years, 13 over the age of 18), the incidence of cardiomyopathy is constant (approximately 65%), while arrhythmia seems to be common in the younger cohort (Abe et al., 2012; Lin et al., 2011; White et al., 2005; Levin et al., 2018). Age of onset of cardiac problems and longitudinal follow-up of cardiomyopathy is largely under-reported. Only four of the 22 adults referenced previously had age of onset of cardiomyopathy provided with two reportedly diagnosed as adults, age 16 and 26 years, respectively (White et al., 2005; Abe et al., 2012). Adult-onset GERD was reported in four of 17 adults (White et al., 2005) and three of them were later diagnosed with Chiari I malformation. While GERD is a

common problem in the general population, the potential association with Chiari I malformation in an adult with CS is important. Among 14 adults with brain imaging, four were diagnosed with Chiari I malformation (White et al., 2005; Abe et al., 2012). Vision concerns continue into adulthood. Specific problems reported in adults include keratoconus in two individuals, and retinal dystrophy in two individuals, in addition to more common concerns such as myopia, astigmatism, amblyopia, nystagmus, and hypermetropia (White et al., 2005; Gripp and Demmer, 2013). Tumors and malignancies seem to be rare in adults. To date, the only malignancy reported in adults with CS has been transitional cell carcinoma of the bladder (Beukers et al. 2014; White et al., 2005). Low bone density may be an issue for adults with CS (White et al., 2005; Leoni et al., 2014). While individuals may have symptomatic low bone density, other comorbidities for low bone density may be present and, therefore, the causal relationship with CS is unclear. A recent study reported bone density in a group of individuals with CS, including four individuals over age 18. While bone density was low in three of the four individuals (lumbar spine and whole body z scores < -2), none of the individuals in the study had a fracture (Leoni et al., 2014). Orthopedic surgeries performed in older individuals include calcaneal tendon lengthening and spinal fusion. One individual had total hip replacement at age 19.

Physical features of individuals with CS change with age, with coarsening of facial features, and loss and thinning of hair. Quality of life is generally reported to be good in adults with CS (Hopkins et al., 2010). One major concern that deserves further investigation is anxiety symptoms (Weaver, unpublished observation). Cognitive function appears stable over time but has been poorly studied in adults. Among a group of 16 adults recently surveyed with mean age of 24.75 years (median 22.5 years, range 16-38 years, SD 6.5), 13 live with their parents, two live in a group home, and one lives semi-independently in an apartment near her parents. Three individuals attend a college program. All

participate in daily activities such as volunteer work or part-time employment. In light of the high likelihood that an adult with CS will require life-long assistance with activities of daily living, it is important for parents or caregivers to begin planning early for continued support of their adult son or daughter with CS. The life expectancy is in need of further study, but as evidenced by the studies summarized above, many individuals survive into adulthood. Among 23 deceased individuals summarized in 2011, only two passed away as adults (Lin et al., 2011). Both were males who died suddenly, at age 27 and 47 years, respectively. The 27-year-old had known severe hypertrophic cardiomyopathy, arrhythmia, and ascending aortic dilation. The 47-year-old was the oldest reported living person with CS at the time of his death and had previously had a normal echocardiogram. In the event of unexpected death, it can be helpful to have previously considered whether autopsy or tissue/DNA preservation is desired and to have an appropriate plan in place. In addition to routine screening for the CS-specific concerns (Table I), it is important to emphasize routine adult health maintenance recommendations, such as annual blood pressure and lipid panel screening in all individuals and mammography in women.

SUMMARY

CS is a RASopathy due to activating germline mutations in the gene *HRAS*. Due to the ubiquitous nature in which *HRAS* is expressed, CS is a complex syndrome affecting multiple organ systems and individuals are predisposed to cancer. Like other RASopathies, CS individuals have distinctive craniofacial features, cardiac anomalies, growth and developmental delays, as well as dermatological, orthopedic, ocular, and neurological issues. It is essential that patients be evaluated by specialists and have continued follow-up in a regular, multidisciplinary approach. These recommendations were

GRIPP ET AL

developed by an interdisciplinary team of experts with the overall goal to provide health care providers with the most timely health care practices and medical management guidelines for individuals with CS across their life span. However, because the full natural history of CS is unclear and systematically obtained data regarding the benefits of these management recommendations are currently lacking, these care guidelines will be refined in the future.

ACKNOWLEDGEMENTS

The authors would like to thank the families and the past NIH supported RASopathy scientific meetings that led to interaction between the clinicians, families and researchers. In addition, we are grateful to the Costello Syndrome Family Network for their enthusiastic support, assistance and thoughtful comments in the development of these guidelines. This work was partially support by the National Institute of Arthritis and Musculoskeletal and Skin Diseases R01AR062165 (K.A.R.) and the Children's Miracle Network (S.P.S.).

REFERENCES

- Abe Y, Aoki Y, Kuriyama S, Kawame H, Okamoto N, Kurosawa K, Ohashi H, Mizuno S, Ogata T, Kure S, Niihori T, Matsubara Y (2012). Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan: findings from a nationwide epidemiological survey. *Am J Med Genet A*, 158A(5), 1083-1094. doi: 10.1002/ajmg.a.35292.
- Adams W. Lectures on the pathology and treatment of lateral and other forms of curvature of the spine. London: Churchill; 1865.
- Adviento, B, Corbin, IL, Widjaja, F, Desachy, G, Enrique, N, Rosser, T, Risi S, Marco EJ, Hendren RL, Bearden CE, Rauen KA, Weiss, LA. (2014). Autism traits in the RASopathies. *J Med Genet*, 51(1), 10-20. doi: 10.1136/jmedgenet-2013-101951.
- Alexander S, Ramadan D, Alkhayyat H, Al-Sharkawi I, Backer KC, El-Sabban F, Hussain K. (2005) Costello syndrome and hyperinsulinemic hypoglycemia. *Am J Med Genet A*. 139(3), 227-30. doi:10.1002/ajmg.a.31011.
- Alfieri P, Piccini G, Caciolo C, Perrino F, Gambardella ML, Mallardi M, Cesarini L, Leoni C, Leone D, Fossati C, Selicorni A, Digilio MC, Tartaglia M, Mercuri E, Zampino G, Vicari S. (2014) Behavioral profile in RASopathies. *Am J Med Genet A*. 164A(4):934-42. doi: 10.1002/ajmg.a.36374.
- Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. *Nat Genet*, 37(10), 1038-40. doi: 10.1038/ng1641.
- Assadi FK, Scott CI Jr, McKay CP, Nicholson L, Cafone M, Hopp L, Fattori DA. (1999). Hypercalciuria and urolithiasis in a case of Costello syndrome. *Pediatr Nephrol*, 13(1), 57-9.
- Axelrad ME, Glidden R, Nicholson L, Gripp KW. (2004). Adaptive skills, cognitive, and behavioral characteristics of Costello syndrome. *Am J Med Genet A*, 128A(4), 396-400. doi:10.1002/ajmg.a.30140.
- Axelrad ME, Nicholson L, Stabley DL, Sol-Church K, Gripp KW. (2007). Longitudinal assessment of cognitive characteristics in Costello syndrome. *Am J Med Genet A*, 143A(24), 3185-93. doi:10.1002/ajmg.a.31968.
- Axelrad ME, Schwartz DD, Fehlis J, Stabley D, Sol-Church K, Gripp KW. (2009). Longitudinal course of cognitive, adaptive, and behavioral characteristics in Costello syndrome. *Am J Med Genet A*, 149A(12), 2666-72. doi: 10.1002/ajmg.a.33126.
- Axelrad ME, Schwartz DD, Katzenstein JM, Hopkins E, Gripp KW. (2011). Neurocognitive, adaptive, and behavioral functioning of individuals with Costello syndrome: a review. *Am J Med Genet C Semin Med Genet*, 157C (2), 115-22. doi: 10.1002/ajmg.c.30299.

Beukers W, Hercegovac A, Zwarthoff EC. (2014). HRAS mutations in bladder cancer at an early age and the possible association with Costello syndrome. *Eur J Human Genet* 22:837-839.

Bizaoui V, Gage J, Brar R, Rauen KA, Weiss LA. (2018). RASopathies are associated with a distinct personality profile. *Am J Med Genet B Neuropsychiatr Genet.* 177(4), 434-46. doi: 10.1002/ajmg.b.32632.

Bowron A, Scott JG, Brewer C, Weir P. (2005). Increased HVA detected on organic acid analysis in a patient with Costello syndrome. *J Inherit Metab Dis* 28(6), 1155-6. doi:10.1007/s10545-005-0124-8.

Bradley DJ, Fischbach PS, Law IH, Serwer GA, Dick M 2nd. (2001). The clinical course of multifocal atrial tachycardia in infants and children. *J Am Coll Cardiol* 38(2), 401-8.

Burkitt-Wright EM, Bradley L, Shorto J, McConnell VP, Gannon C, Firth HV, Park SM, D'Amore A, Munyard PF, Turnpenny PD, Charlton A, Wilson M, Kerr B. (2012). Neonatal lethal Costello syndrome and unusual dinucleotide deletion/insertion mutations in HRAS predicting p.Gly12Val. *Am J Med Genet A* 158A(5), 1102-10. doi: 10.1002/ajmg.a.35296.

Cakir M, Arici C, Tacoy S, Karayalcin U. (2004). A case of Costello with parathyroid adenoma and hyperprolactinemia. *Am J Med Genet A.* 124A(2):196-9. doi:10.1002/ajmg.a.20361.

Calabria AC, Gallagher PR, Simmons R, Blinman T, De León DD. (2011). Postoperative surveillance and detection of postprandial hypoglycemia after fundoplasty in children. *J Pediatr.* 159(4), 597-601.e1. doi: 10.1016/j.jpeds.2011.03.049.

Calandrelli R, D'Apolito G, Marco P, Zampino G, Tartaglione T, Colosimo C. (2015). Costello syndrome: Analysis of the posterior cranial fossa in children with posterior fossa crowding. *Neuroradiol J*, 28(3), 254-8. doi: 10.1177/1971400915592549.

Cesarini L, Alfieri P, Pantaleoni F, Vasta I, Cerutti M, Petrangeli V, Mariotti P, Leoni C, Ricci D, Vicari S, Selicorni A, Tartaglia M, Mercuri E, Zampino G. (2009). Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade. *Am J Med Genet A* 149A(2), 140-6. doi: 10.1002/ajmg.a.32488.

Chiu AT, Zhu L, Mok GT, Leung GK, Chow CB, Chung BH. (2016). Before and after - Nutritional transformation of dysmorphism in a case of Costello syndrome. *Eur J Med Genet.* 59(11), 573-576. doi: 10.1016/j.ejmg.2016.10.001.

Costello JM. (1971). A new syndrome. *NZ Med J* 74, 397.

Costello JM. (1977). A new syndrome: mental subnormality and nasal papillomata. *Aust Paediatr J* 13(2), 114-8.

Costello JM. (1996). Costello syndrome: Update on the original cases and commentary. *Am J Med Genet* 62(2), 199–201. doi:10.1002/ajmg.1320620203.

Della Marca G, Vasta I, Scarano E, Rigante M, De Feo E, Mariotti P, Rubino M, Vollono C, Mennuni GF, Tonali P, Zampino G. (2006). Obstructive sleep apnea in Costello syndrome. *Am J Med Genet A* 140(3), 257–62. doi:10.1002/ajmg.a.31076.

Delrue MA, Chateil JF, Arveiler B, Lacombe D. (2003). Costello syndrome and neurological abnormalities. *Am J Med Genet A*, 123A(3), 301-5. doi:10.1002/ajmg.a.20330.

Der Kaloustian VM, Moroz B, McIntosh N, Watters AK, Blaichman S. (1991). Costello syndrome. *Am J Med Genet* 41(1), 69–73.

Detweiler S, Thacker MM, Hopkins E, Conway L, Gripp KW (2013). Orthopedic manifestations and implications for individuals with Costello syndrome. *Am J Med Genet A* 161A(8), 1940-9. doi:10.1002/ajmg.

Dickson PI, Briones NY, Baylen BG, Jonas AJ, French SW, Lin HJ. (2004). Costello syndrome with pancreatic islet cell hyperplasia. *Am J Med Genet A*, 130A(4), 402-5. doi: 10.1002/ajmg.a.30288.

Digilio MC, Sarkozy A, Capolino R, Chiarini Testa MB, Esposito G, de Zorzi A, Cutrera R, Marino B, Dallapiccola B. (2008). Costello syndrome: clinical diagnosis in the first year of life. *Eur J Pediatr*, 167(6), 621-8. doi: 10.1007/s00431-007-0558-0.

Dileone M, Profice P, Pilato F, Alfieri P, Cesarini L, Mercuri E, Leoni C, Tartaglia M, Di Iorio R, Zampino G, Di Lazzaro V. (2010). Enhanced human brain associative plasticity in Costello syndrome. *J Physiol*, 588(Pt 18), 3445-56. doi:10.1113/jphysiol.2010.191072.

Di Rocco M, Doderio P. (2003). Concerning “Five additional Costello syndrome patients with rhabdomyosarcoma: Proposal for a tumour screening protocol”. *Am J Med Genet* 118A(2), 199.

Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA. (2006). HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. *Am J Med Genet A*, 140(1), 8–16. doi:10.1002/ajmg.a.31078.

Flores-Nava G, Canun-Serrano S, Moysen-Ramirez SG, Parraguirre-Martinez S, Escobedo-Chavez E. (2000). Costello syndrome associated to a neuroblastoma. Presentation of a case. *Gac Med Mex* 136(6), 605-9.

Franceschini P, Licata D, Di Cara G, Guala A, Bianchi M, Ingrosso G, Franceschini D (1999). Bladder carcinoma in Costello syndrome: report on a patient born to consanguineous parents and review. *Am J Med Genet*, 86(2), 174-9.

Galéra C, Delrue MA, Goizet C, Etchegoyhen K, Taupiac E, Sigaudy S, Arveiler B, Philip N, Bouvard M, Lacombe D. (2006) Behavioral and temperamental features of children with Costello syndrome. *Am J Med Genet A*. 140(9):968-74.

Ganz JB, Davis JL, Lund EM, Goodwyn FD, Simpson RL. (2012). Meta-analysis of PECS with individuals with ASD: Investigation of targeted versus non-targeted outcomes, participant characteristics, and implementation phase. *Res Dev Disabil*, 33(2), 406-18. doi: 10.1016/j.ridd.2011.09.023.

Gelb BD, Roberts AE, Tartaglia M. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute, 2011. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics* 128 Suppl 5, S213–256. (2015). Cardiomyopathies in Noonan syndrome and the other RASopathies. *Prog Pediatr Cardiol* 39(1), 13–19. doi: 10.1016/j.ppedcard.2015.01.002.

Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons. (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J. Thorac. Cardiovasc. Surg.* 142(24), 2761-96. doi: 10.1161/CIR.0b013e318223e230.

Giannoulatou E, McVean G, Taylor IB, McGowan SJ, Maher GJ, Iqbal Z, Pfeifer SP, Turner I, Burkitt Wright EM, Shorto J, Itani A, Turner K, Gregory L, Buck D, Rajpert-De Meyts E, Looijenga LH, Kerr B, Wilkie AO, Goriely A. (2013) Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline. *Proc Natl Acad Sci USA*. 110(50):20152-7. doi: 10.1073/pnas.1311381110.

Girisha KM, Lewis LE, Phadke SR, Kutsche K. (2010). Costello syndrome with severe cutis laxa and mosaic HRAS G12S mutation. *Am J Med Genet A*, 152A(11), 2861-4. doi: 10.1002/ajmg.a.33687.

Gomez-Ospina N, Kuo C, Ananth AL, Myers A, Brennan M-L, Stevenson DA, Bernstein JA, Hudgins L. (2016). Respiratory system involvement in Costello syndrome. *Am J Med Genet A*, 170(7), 1849–57. doi: 10.1002/ajmg.a.37655.

Goodwin AF, Oberoi S, Landan M, Charles C, Massie JC, Fairley C, Rauen KA, Klein OD. (2014a). Craniofacial and dental development in Costello syndrome. *Am J Med Genet A*, 164A(6), 1425-30. doi: 10.1002/ajmg.a.36475.

Goodwin AF, Tidyman WE, Jheon AH, Sharir A, Zheng X, Charles C, Fagin JA, McMahon M, Diekwisch TGH, Ganss B, Rauen KA, Klein OD. (2014b). Abnormal Ras Signaling Negatively Regulates Enamel Formation. *Hum Mol Genet*. 2014 Feb 1;23(3):682-92.

Goriely A, Wilkie AOM. (2012). Paternal Age Effect Mutations and Selfish Spermatogonial Selection: Causes and Consequences for Human Disease. *Am J Hum Genet*, 90(2), 175-200. doi: 10.1016/j.ajhg.2011.12.017.

Grant AR, Cushman BJ, Cavé H, Dillon MW, Gelb BD, Gripp KW, Lee JA, Mason-Suares H, Rauen KA, Tartaglia M, Vincent LM, Zenker M. 2018. Assessing the gene-disease association of 19 genes with the RASopathies using the ClinGen gene curation framework. *Hum Mutat*. 39:1485-1493.

Gregersen N, Viljoen D. (2004). Costello syndrome with growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations. *Am J Med Genet A*, 129A(2), 171-15. doi:10.1002/ajmg.a.30189.

Gripp KW, Scott CI Jr., Nicholson L, Figueroa TE (2000): A second case of bladder carcinoma in a patient with Costello syndrome. *Am J Med Genet* 90:256-259.

Gripp KW, Scott CI, Nicholson L, McDonald-McGinn DM, Ozeran JD, Jones MC, Lin AE, Zackai EH. (2002). Five additional Costello Syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. *Am J Med Genet* 108(1), 80-7.

Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI Jr, Doyle D, Aoki Y, Matsubara Y, Zackai EH, Lapunzina P, Gonzalez-Meneses A, Holbrook J, Agresta CA, Gonzalez IL, Sol-Church K. (2006a). HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. *Am J Med Genet A*, 140(1), 1–7. doi:10.1002/ajmg.a.31047.

Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K. (2006b). Somatic mosaicism for an HRAS mutation causes Costello syndrome. *Am J Med Genet A*, 140(20), 2163–9. doi:10.1002/ajmg.a.31456.

Gripp KW, Lin AE. Costello Syndrome. (2006). In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1507/>.

Gripp KW, Innes AM, Axelrad ME, Gillan TL, Parboosingh JS, Davies C, Leonard NJ, Lapointe M, Doyle D, Catalano S, Nicholson L, Stabley DL, Sol-Church K. (2008). Costello syndrome associated with novel germline HRAS mutations: an attenuated phenotype? *Am J Med Genet A*, 146A(6), 683–90. doi: 10.1002/ajmg.a.32227.

Gripp KW, Hopkins E, Doyle D, Dobyns WB. (2010). High incidence of progressive postnatal cerebellar enlargement in Costello syndrome: brain overgrowth associated with HRAS mutations as the likely cause of structural brain and spinal cord abnormalities. *Am J Med Genet A*, 152A(5), 1161–8. doi:10.1002/ajmg.a.33391.

- Gripp KW, Stabley DL, Geller PL, Hopkins E, Stevenson DA, Carey JC, Sol-Church K. (2011a). Molecular confirmation of HRAS p.G12S in siblings with Costello syndrome. *Am J Med Genet A*, 155A(9),2263–8. doi:10.1002/ajmg.a.34150.
- Gripp KW, Hopkins E, Sol-Church K, Stabley DL, Axelrad ME, Doyle D, Dobyns WB, Hudson C, Johnson J, Tenconi R, Graham GE, Sousa AB, Heller R, Piccione M, Corsello G, Herman GE, Tartaglia M, Lin AE. (2011b). Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C. *Am J Med Genet A*, 155A(4), 706–16. doi: 10.1002/ajmg.a.33884.
- Gripp KW, Lin A. (2012). Costello syndrome: A Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. *Genet Med*, 14(3), 285-92. doi: 10.1038/gim.0b013e31822dd91f.
- Gripp KW, Bifeld E, Stabley DL, Hopkins E, Meien S, Vinette K, Sol-Church K, Rosenberer G. (2012). A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development. *Am J Med Genet A*, 158A(9), 2106-18. doi:10.1002/ajmg.a.35449.
- Gripp, KW, and Demmer, LA. (2013). Keratoconus in Costello syndrome. *Am J Med Genet A*, 161A(5), 1132-6. doi: 10.1002/ajmg.a.35816.
- Gripp KW, Sol-Church K, Smpokou P, Graham GE, Stevenson DA, Hanson H, Viskochil DH, Baker LC, Russo B, Gardner N, Stabley DL, Kolbe V, Rosenberger G. (2015). An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences. *Am J Med Genet A* (9), 2085-97. doi: 10.1002/ajmg.a.37128.
- Gripp KW, Robbins KM, Sheffield BS, Lee AF, Patel MS, Yip S, Doyle D, Stabley D, Sol-Church K. (2016). Paternal uniparental disomy 11p15.5 in the pancreatic nodule of an infant with Costello syndrome: Shared mechanism for hyperinsulinemic hypoglycemia in neonates with Costello and Beckwith-Wiedemann syndrome and somatic loss of heterozygosity in Costello syndrome driving clonal expansion. *Am J Med Genet A*, 170(3), 559-64. doi:10.1002/ajmg.a.37471.
- Gripp KW, Kolbe V, Brandenstein LI, Rosenberger G. (2017). Attenuated phenotype of Costello syndrome and early death in a patient with an HRAS mutation (c.179G>T; p.Gly60Val) affecting signalling dynamics. *Clin Genet*. 92(3), 332-337. doi: 10.1111/cge.12980.
- Hart TC, Zhang Y, Gorry MC, Hart PS, Cooper M, Marazita ML, Marks JM, Cortelli JR, Pallos D. (2002). A mutation in the SOS1 gene causes hereditary gingival fibromatosis type 1. *Am J Hum Genet* 70: 943–954.
- Hartung A-M, Swensen J, Uriz I, Lapin M, Kristjansdottir K, Peterson USS, Bang JMV, Guerra B, Anderson HS, Dobrowolski SF, Careys JC, Yu P, Vaughn C, Calhoun A, Larsen MR, Dyrskjøt L, Stevenson D, Andresen BS. (2017). The Splicing Efficiency of Activating HRAS Mutations Can

Determine Costello Syndrome Phenotype and Frequency in Cancer. *PLoS Genet*, 12(5)
doi:10.1371/journal.pgen.1006039.

Hennekam RC. (2003). Costello Syndrome: An Overview. *Am J Med Genet C Simin Med Genet*, 117C(1), 42-8. doi:10.1002/ajmg.a.10019.

Hopkins E, Lin AE, Krepkovich KE, Axelrad ME, Sol-Church K, Stabley DL, Hossain J, Gripp KW. (2010). Living with Costello syndrome: quality of life issues in older individuals. *Am J Med Genet A* 152A(1), 84-90. doi: 10.1002/ajmg.a.33147.

Kawame H, Matsui M, Kurosawa K, Matsuo M, Masuno M, Ohashi H, Fueki N, Aoyama K, Miyatsuka Y, Suzuki K, Akatsuka A, Ochiai Y, Fukushima Y. (2003). Further delineation of the behavioral and neurologic features in Costello Syndrome. *Am J Med Genet A*, 118A(1), 8-14. doi:10.1002/ajmg.a.10236.

Kerr B, Eden OM, Dandamudi R, Shannon N, Quarrell O, Emmerson A, Ladusans E, Gerrard M, Donnai D. (1998). Costello syndrome: two cases with embryonal rhabdomyosarcoma. *J Med Genet* 35(12), 1036-9.

Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden OB, O'Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cavé H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G. (2006). Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. *J Med Genet*, 43(5), 401-5. doi:10.1136/jmg.2005.040352.

Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosesnberg PS. (2011). Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. *Am J Med Genet C Semin Med Genet* 157C(2),83-9. doi: 10.1002/ajmg.c.30300.

Leoni C, Stevenson DA, Martini L, De Sanctis R, Mascolo G, Pantaleoni F, De Santis S, La Torraca I, Persichilli S, Caradonna P, Tartaglia M, Zampino G. (2014). Decreased bone mineral density in Costello syndrome. *Mol Genet Metab*, 111(1), 41-5. doi:10.1016/j.ymgme.2013.08.007.

Leoni C, Onesimo R, Giorgio V, Diamanti A, Giorgio D, Martini L, Rossodivita A, Tartaglia M, Zampino G. (2016). Understanding growth failure in Costello syndrome: increased resting energy expenditure. *J Pediatr* 2016; 170: 322-4. doi: 10.1016/j.jpeds.2015.11.076.

Levin MD, Saitta SC, Gripp KW, Wenger TL, Ganesh J, Kalish JM, Epstein MR, Smith R, Czosek RJ, Ware SM, Goldenberg P, Myers A, Chatfield KC, Gillespie MJ, Zackai EH, Lin AE. (2018). Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients. *Am J Med Genet A*,176(8),1711-1722. doi: 10.1002/ajmg.a.38854.

Lightdale JR, Gremse DA; Section on Gastroenterology, Hepatology, and Nutrition. (2013). Gastroesophageal reflux: management guidance for the pediatrician. *Pediatrics*. 131(5), e1684-95. doi: 10.1542/peds.2013-0421.

Lin AE, O'Brien B, Demmer LA, Almeda KK, Blanco CL, Glasow PF, Berul CI, Hamilton R, Micheil Innes A, Lauzon JL, Sol-Church K, Gripp KW. (2009). Prenatal features of Costello syndrome: ultrasonographic findings and atrial tachycardia. *Prenat Diagn*, 29(7), 682–90. doi:10.1002/pd.2276.

Lin AE, Alexander ME, Colan SD, Kerr B, Rauen KA, Noonan J, Baffa J, Hopkins E, Sol-Church K, Limongelli G, Digilio MC, Marino B, Innes AM, Aoki Y, Silberbach M, Delrue MA, White SM, Hamilton RM, O'Conner W, Grossfeld PD, Smoot LB, Padera RE, Gripp KW. (2011). Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. *Am J Med Genet A* 155A(3), 486-507. doi: 10.1002/ajmg.a.33857.

Lo IF, Brewer C, Shannon N, Shorto J, Tang B, Black G, Soo MT, Ng DK, Lam ST, Kerr B. (2008). Severe neonatal manifestations of Costello syndrome. *J Med Genet*, 45(3), 167–71. doi:10.1136/jmg.2007.054411.

Lorenz S, Petersen C, Kordaß U, Seidel H, Zenker M, Kutsche K. (2012). Two cases with severe lethal course of Costello syndrome associated with HRAS p.G12C and p.G12D. *Eur J Med Genet* 55(11), 615–619. doi: 10.1016/j.ejmg.2012.07.007.

Lorenz S, Lissewski C, Simsek-Kiper PO, Alanay Y, Boduroglu K, Zenker M, Rosenberger G. (2013). Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome. *Hum Mol Genet*, 22(8), 1643-53. doi: 10.1093/hmg/ddt014.

Martin RA, Jones KL. (1991). Delineation of the Costello syndrome. *Am J Med Genet* 41(3), 346-9. doi:10.1002/ajmg.1320410316.

Morice-Picard F, Ezzedine K, Delrue MA, Arveiler B, Fergelot P, Taïeb A, Lacombe D, Boralevi F. (2013). Cutaneous manifestations in Costello and cardiofaciocutaneous syndrome: report of 18 cases and literature review. *Pediatr Dermatol*, 30(6), 665-73. doi: 10.1111/pde.12171.

Moroni I, Bedeschi F, Luksch R, Casanova M, D'Incerti L, Uziel G, Selicorni A. (2000). Costello syndrome: a cancer predisposing syndrome? *Clin Dysmorphol* 9(4), 265-8.

Myers A, Bernstein JA, Brennan ML, Curry C, Esplin ED, Fisher J, Homeyer M, Manning MA, Muller EA, Niemi AK, Seaver LH, Hintz SR, Hudgins L. (2014) Perinatal features of the RASopathies: Noonan syndrome, cardiofaciocutaneous syndrome and Costello syndrome. *Am J Med Genet A*, 164A(11), 2814-21. doi: 10.1002/ajmg.a.36737.

Narrod SA, Stiller C, Lenoir GM. (1991). An estimate of the heritable fraction of childhood cancer. *Br J Cancer* 63, 993-999.

Paquin A, Hordo C, Kaplan DR, Miller FD. (2009). Costello syndrome H-Ras alleles regulate cortical development. *Dev Biol* 330(2), 440-451. doi: 10.1016/j.ydbio.2009.04.010.

- Piccione M, Piro E, Pomponi MG, Matina F, Pietrobono R, Candela E, Gabriele B, Neri G, Corsello G. (2009). A premature infant with Costello syndrome due to a rare G13C HRAS mutation. *Am J Med Genet A*, 149A(3), 487-9. doi: 10.1002/ajmg.a.32674.
- Pierpont ME, Richards M, Engel WK, Mendelsohn NJ, Summers CG. (2017) Retinal dystrophy in two boys with Costello syndrome due to the HRAS p.Gly13Cys mutation. *Am J Med Genet A*. 173(5):1342-1347. doi: 10.1002/ajmg.a.38110.
- Quezada E, Gripp KW. (2007). Costello syndrome and related disorders. *Curr Opin Pediatr*, 19(6), 636-44. doi:10.1097/MOP.0b013e3282f161dc.
- Rauen, KA. (2007). HRAS and the Costello syndrome. *Clin Genet*, 71(2), 101-8. doi:10.1111/j.1399-0004.2007.00743.x
- Rauen, KA. (2013). The RASopathies. *Annu Rev Genomics Hun Genet*, 14, 355-69. doi: 10.1146/annurev-genom-091212-153523.
- Reinker KA, Stevenson DA, Tsung A. (2011). Orthopaedic conditions in Ras/MAPK related disorders. *J Pediatr Orthop*, 31(5), 599-605. doi: 10.1097/BPO.0b013e318220396e.
- Robbins KM, Stabley DL, Holbrook J, Sahraoui R, Sadreameli A, Conard K, Baker L, Gripp KW, Sol-Church K. 2016. Paternal uniparental disomy with segmental loss of heterozygosity of chromosome 11 are hallmark characteristics of syndromic and sporadic embryonal rhabdomyosarcoma. *Am J Med Genet Part A* 170:3197-3206.
- Salerno JC, Kertesz NJ, Friedman RA, Fenrich AL. (2004). Clinical course of atrial ectopic tachycardia is age-dependent: results and treatment in children < 3 or > or =3 years of age. *J. Am. Coll. Cardiol.* 43(3), 438-444. doi:10.1016/j.jacc.2003.09.031.
- Sammon MR, Doyle D, Hopkins E, Sol-Church K, Stabley DL, McGready J, Schulze K, Alade Y, Hoover-Fong J, Gripp KW. (2012). Normative growth charts for individuals with Costello syndrome. *Am J Med Genet A*. 158A(11), 2692-9. doi: 10.1002/ajmg.a.35534.
- Schwartz DD, Katzenstein JM, Hopkins E, Stabley DL, Sol-Church K, Gripp KW, Axelrad ME. (2013). Verbal memory functioning in adolescents and young adults with Costello syndrome: Evidence for relative preservation in recognition memory. *Am J Med Genet A*, 161A(9), 2258-2265. doi: 10.1002/ajmg.a.36078.
- Schwartz DD, Katzenstein JM, Highley EJ, Stabley DL, Sol-Church K, Gripp KW, Axelrad ME. (2017). Age-Related Differences in Prevalence of Autism Spectrum Disorder Symptoms in Children and Adolescents with Costello Syndrome. *Am J Med Genet A*, 173(5), 1294-1300. doi: 10.1002/ajmg.a.38174.

Shankar SP, Rauen KA. (2009). A Recurring Mutation G12S in HRAS causes Variable Ocular Phenotype in Costello Syndrome; (252/F PB#40) presented at The American Society of Human Genetics, Oct 23, 2009, Honolulu, HI.

Sheffield BS, Yip S, Ruchelli ED, Dunham CP, Sherwin E, Brooks PA, Sur A, Singh A, Human DG, Patel MS, Lee A. (2015). Fatal congenital hypertrophic cardiomyopathy and a pancreatic nodule morphologically identical to focal lesion of congenital hyperinsulinism in an infant with Costello syndrome. case report and review of the literature. *Pediatr Dev Pathol* 18(3), 237-44. doi: 10.2350/14-07-1525-CR.1

Sigaudy S, Vittu G, David A, Vigeron J, Lacombe D, Moncla A, Fiori E, Philip N. (2000). Costello syndrome: report of six patients including one with an embryonal rhabdomyosarcoma. *Europ J Pediatr* 159(3),139-42.

Siegel DH, Mann JA, Krol AL, Rauen KA. (2012). Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development. *Br J Dermatol*, 166(3), 601-7. doi: 0.1111/j.1365-2133.2011.10744.x.

Smith LP, Podraza J, Proud VK. (2009). Polyhydramnios, fetal overgrowth and macrocephaly: Prenatal ultrasound findings of Costello syndrome. *Am J Med Genet A*, 149A(4), 779–84. doi: 10.1002/ajmg.a.32778.

Sol-Church K, Stabley DL, Nicholson L, Gonzalez IL, Gripp KW. (2006). Paternal bias in parental origin of HRAS mutations in Costello syndrome. *Hum Mutat*, 27(8), 736–41. doi:10.1002/humu.20381.

Sol-Church K, Stabley DL, Demmer LA, Agbulos A, Lin AE, Smoot L, Nicholson L, Gripp KW. (2009). Male-to-male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism. *Am J Med Genet A*, 149A(3), 315–21. doi: 10.1002/ajmg.a.32639.

Sol-Church K, Gripp KW. (2009). Noonan Syndrome and Related Disorders - A Matter of Deregulated Ras Signaling. Zenker M (ed). Basel, Switzerland, Karger.

Sriboonnark L, Aurora H, Falto-Aizpurua L, Choudhary S, Connelly EA. (2015). Costello syndrome with severe nodulocystic acne: unexpected significant improvement of acanthosis nigricans after oral isotretinoin treatment. *Case Rep Pediatr*, 934865. doi: 10.1155/2015/934865.

Stein RI, Legault L, Daneman D, Weksberg R, Hamilton J. (2004). Growth hormone deficiency in Costello syndrome. *Am J Med Genet A*. 129A(2), 166-70. doi:10.1002/ajmg.a.30187

Stevenson DA, Schwarz EL, Carey JC, Viskochil DH, Hanson H, Bauer S, Weng HY, Greene T, Reinker K, Swensen J, Chan RJ, Yang FC, Senbanjo L, Yang Z, Mao R, Pasquali M. (2011). Bone resorption in syndromes of the Ras/MAPK pathway. *Clin Genet*, 80(6), 566-73. doi: 10.1111/j.1399-0004.2010.01619.x.

Stevenson DA, Yang FC. (2011). The musculoskeletal phenotype of the RASopathies. *Am J Med Genet C*. 157C(2), 90-103. doi: 10.1002/ajmg.c.30296.

Stevenson DA, Allen S, Tidyman WE, Carey JC, Viskochil DH, Stevens A, Hanson H, Sheng X, Thompson BA, Okumura MJ, Reinker K, Johnson B, Rauen KA. (2012). Peripheral muscle weakness in RASopathies. *Muscle Nerve*, 46(3), 394-9. doi: 10.1002/mus.23324.

Suri M, Garrett C. (1998). Costello syndrome with acoustic neuroma and cataract. Is the Costello locus linked to neurofibromatosis type 2 on 22q? *Clin Dysmorphol* 7(2), 149-51.

Takahashi M, Ohashi H. (2013). Craniofacial and dental malformations in Costello syndrome: a detailed evaluation by using multi-detector row computed tomography. *Congenit Anom (Kyoto)* 53(2), 67-72. doi: 10.1111/cga.12004.

Thornton PS, Stanley CA, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Rozance PJ, Simmons RA, Sperling MA, Weinstein DA, White NH, Wolfsdorf JI; Pediatric Endocrine Society. (2015). Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. *J Pediatr*. 167(2), 238-45. doi: 10.1016/j.jpeds.2015.03.057.

Tidyman WE, Lee HS, Rauen KA. (2011). Skeletal muscle pathology in Costello and cardio-facio-cutaneous syndrome: developmental consequences of germline Ras/MAPK activation on myogenesis. *Am J Med Genet C Semin Med Genet* 157C(2), 104-14. doi: 10.1002/ajmg.c.30298.

Tidyman, WE, Rauen KA. (2016a). Expansion of the RASopathies. *Curr Genet Med Rep*, 4(3), 57–64.

Tidyman, WE, Rauen, KA. (2016b). Pathogenetics of the RASopathies. *Hum Mol Genet*, 25, R123-R132.

Urakami S, Igawa M, Shiina H, Shigeno K, Kikuno N, Yoshino T. (2002). Recurrent transitional cell carcinoma in a child with the Costello syndrome. *J Urol* 168(3), 1133-4.

Van den Bosch T, Van Schoubroeck D, Fryns JP, Naulaers G, Inion AM, Devriendt K. (2002). Prenatal findings in a monozygotic twin pregnancy with Costello syndrome. *Prenat Diagn*, 22(5), 415-7. doi:10.1002/pd.333.

van der Burgt I, Kupsy W, Stassou S, Nadroo A, Barroso C, Diem A, Kratz CP, Dvorsky R, Ahmadian MR, Zenker M. (2007). Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. *J Med Genet*, 44(7), 459–62. doi:10.1136/jmg.2007.049270.

van Steensel MA, Vreeburg M, Peels C, van Ravenswaaij-Arts CM, Bijlsma E, Schrandt-Stumpel CT, van Geel M. (2006). Recurring HRAS mutation G12S in Dutch patients with Costello syndrome. *Exp Dermatol*, 15(9), 731-4. doi:10.1111/j.1600-0625.2006.0047.x.

Villani A, Greer MC, Kaslish JM, Nakagawara A, Nathanson KL, Pajtler KW, Pfister SM, Walsh MF, Wasserman JD, Zelle K, Kratz CP. (2017). Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk. *Clin Cancer Res*, 23(12), e83-e90. doi: 10.1158/1078-0432.CCR-17-0631.

White SM, Graham JM Jr, Kerr B, Gripp K, Weksberg R, Cytrynbaum C, Reeder JL, Stewart FJ, Edwards M, Wilson M, Bankier A. (2005). The adult phenotype in Costello syndrome. *Am J Med Genet A* 136(2), 128-35. doi:10.1002/ajmg.a.30747.

Weaver KN, Wang D, Cnota J, Gardner N, Stabley D, Sol-Church K, Gripp KW, Witte DP, Bove KE, Hopkin RJ. (2014). Early-lethal Costello syndrome due to rare HRAS Tandem Base substitution (c.35_36GC>AA; p.G12E)-associated pulmonary vascular disease. *Pediatr Dev Pathol*. 17(6), 421-30. doi: 10.2350/14-05-1488-OA.1

Xu F, Wang HJ, Lin ZM, Yu B. (2015). Recurrent duplication mutation in HRAS causing mild Costello syndrome in a Chinese patient. *Clin Exp Dermatol*, 40(4), 404-7. doi: 10.1111/ced.12571.

Yassir Wk, Grottkau BE, Goldberg MJ. (2003). Costello syndrome: orthopaedic manifestations and functional health. *J Pediatr Orthop* 23(1), 94-8.

Young O, Perati S, Weiss LA, Rauen KA. (2018) Age and ASD symptoms in Costello syndrome. *Am J Med Genet A*. 176(4), 1027-8. doi: 10.1002/ajmg.a.38641.

Zampino G, Mastroiacovo P, Ricci R, Zollini M, Segni G, Martini-Neri ME, Neri G. (1993). Costello syndrome: Further clinical delineation, natural history genetic definition and nosology. *Am J Med Genet* 47(2), 176-83. doi: 10.1002/ajmg.1320470210.

Zampino G, Pantaleoni F, Carta C, Cobellis G, Vasta I, Neri C, Pogna EA, De Feo E, Delogu A, Sarkozy A, Atzeri F, Selicorni A, Rauen KA, Cytrynbaum CS, Weksberg R, Dallapiccola B, Ballabio A, Gelb BD, Neri G, Tartaglia M. (2007). Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. *Hum Mutat*, 28(3), 265-72. doi:10.1002/humu.20431.

FIGURE LEGENDS

Figure 1. Images of an individual male with the most common heterozygous HRAS p.G12S missense mutation. The images demonstrate the classical Costello syndrome craniofacial phenotype. This figure depicts the evolution of his features from birth (A), to five months of age (B), one and one-half years of age (C), four and one-half years of age (D), 15 years of age (E) and 23 years of age (F).

Figure 2. Images of individuals with rarer HRAS mutations. A) A three-year-old boy with a heterozygous HRAS p.F156L missense mutation. B) A three-year-old girl with a heterozygous HRAS p.Q22K missense mutation. C) A three and one-half-year-old boy with a heterozygous HRAS p.G12A missense mutation. D) A five and one-half-year-old girl with a heterozygous HRAS p.G12C missense mutation. E) A six-year-old girl with a heterozygous HRAS p.G13C missense mutation. F) A 26-year-old man with a heterozygous HRAS p.G13D missense mutation.

Table II. Differential Diagnosis of Costello Syndrome

SYNDROME	COMMON FEATURES WITH CS	DIFFERENCES WITH CS
Noonan syndrome	Hypertelorism, downslanting palpebral fissures, ptosis, short stature, relative macrocephaly, PVS, HCM, ASD, hypotonia, some with neurocognitive delay.	Facial features less coarse, lower incidence of severe feeding problems, fewer cutaneous features, lower incidence of neurocognitive delay.
Cardio-facio-cutaneous syndrome	Hypertelorism, downslanting palpebral fissures, curly hair, broad nasal bridge, epicanthal folds, PVS, HCM, pectus deformity, short stature, feeding difficulties, hypotonia, neurocognitive delay.	Facial features less coarse, higher incidence of neurocognitive delay, seizures, progressive mole formation, keratosis pilaris, ulerythema ophryogenes,
Noonan syndrome with multiple lentigenes (formerly LEOPARD syndrome)	Short stature, hypertelorism, PVS, HCM, conduction abnormalities, hypotonia, some with cognitive delay.	Multiple skin lentigenes, frequent sensorineural deafness, conduction abnormalities.
Noonan syndrome with loose anagen hair	Triangular facies, macrocephaly, hypertelorism, high forehead, sparse thin hair, short stature, eczema, dry skin, hyperpigmentation, hypotonia.	After infancy facial features less coarse, mitral valve dysplasia.
Beckwith-Wiedemann syndrome	Macrosomia at birth, coarse facial features, neonatal hypoglycemia, HCM, visceromegaly, hypotonia, embryonal tumors.	Ear creases/pits, macroglossia, omphalocele, renal abnormalities, hemihyperplasia.
Simpson-Golabi-Behmel syndrome	Macrosomia, coarse facial features, visceromegaly, developmental delay.	Macroglossia, renal anomalies, cleft lip, polydactyly.
Williams syndrome	Coarse facial features, full lips with large mouth, soft skin, ligamentous laxity, hyponotonia, feeding difficulties.	Elastin arteriopathy, peripheral pulmonary stenosis, supraaortic stenosis, unique personality characteristics, hypercalcemia.
Lysosomal storage disorders	Coarse facial features, hypotonia.	Does not have serum and urine biochemical profile.

Table III. Genotype-phenotype correlations in Costello syndrome

HRAS MUTATION	CLINICAL PHENOTYPE
p.G12S	Classic features of CS
p.G12C	Severe neonatal phenotype - severe cardiomyopathy, pleural and pericardial effusion, and lung abnormalities
p.G12D	Severe neonatal phenotype - severe cardiomyopathy, pleural and pericardial effusion, and lung abnormalities
p.G12A	Higher rate of malignancy
p.G12V	Severe cardiomyopathy and tachycardia as well as respiratory distress; typically lethal
p.G13C	Milder symptoms with lower risk for malignant tumors or papillomata, taller stature, and absence of the classic CS ulnar wrist deviation
p.Q22K	Classic features of CS plus congenital myopathy
p.T58I	Facial features tend to be less coarse
p.G60D	Milder phenotype – reported with maternal transmission
p.G60V	Only one case reported - infant death
p.E63K	Classic features of CS plus congenital myopathy
p.E63_D69dup	Milder symptoms - milder intellectual disability, fewer feeding issues, and a lower risk of tumors
p.K117R	Facial features tend to be less coarse
p.A146P	Facial features tend to be less coarse
p.A146T	Milder symptoms - minor skin and joint involvement, and milder growth restriction. Microcephaly and sparse, thin hair are also reported.
p.A146V	Facial features tend to be less coarse

Table I – Costello Syndrome Management Recommendations

Clinical Specialty	Recommendations
Molecular Genetics	<p><u>At risk for:</u> All individuals suspected or known to have Costello syndrome should have a thorough evaluation with medical genetics</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Genetics consultation with comprehensive physical exam and a review of prenatal, postnatal, developmental, and family history • Genetic testing coordinated by a genetics professional is important to confirm the diagnosis <ul style="list-style-type: none"> ○ <i>HRAS</i> sequencing, or common mutation panel followed by full analysis if common panel is negative ○ Multi-gene RASopathies panel if diagnosis is unclear or negative <i>HRAS</i> testing ○ Additional testing may be considered by medical genetics professionals including chromosome microarray and exome testing • Parental testing should be considered when a variant of uncertain significance is detected or parental symptoms are noted • For prenatal testing due to ultrasound findings, consider RASopathies panel as a first-tier test given overlap in symptoms and limitations of phenotypic assessment by ultrasound • Molecular testing should be done in adults with a clinical diagnosis of Costello syndrome to confirm diagnosis and clarify risks of specific symptoms <p><u>Ongoing Management:</u></p> <ul style="list-style-type: none"> • Annual follow-up with medical genetics for continued health assessment and referrals as needed for subspecialty care
Cardiology	<p><u>At risk for:</u> Pulmonic valve stenosis, hypertrophic cardiomyopathy (HCM), arrhythmia, septal defects, aortic dilation</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Consultation with pediatric cardiologist • Echocardiogram (echo), electrocardiogram (ECG), Holter monitor <p><u>Ongoing Management:</u></p> <ul style="list-style-type: none"> • Known cardiac disease: <ul style="list-style-type: none"> ○ Cardiology follow-up based on type and severity of disease; individualized care for medical management, intervention or surgical correction/palliation ○ For apparently resolved HCM, maintain surveillance for recurrence or remodeling <ul style="list-style-type: none"> ▪ For other apparently resolved CVD (ex. arrhythmia,

	<p>pulmonic valve stenosis) maintain surveillance for adolescent or adult with no known cardiac disease</p> <ul style="list-style-type: none"> • No known cardiac disease: <ul style="list-style-type: none"> ○ Age 0-2: frequent (3-6 months) evaluation by pediatric cardiologist with ECG, echo every 6 months Holter for tachycardia or irregular rhythm ○ Age 2-20: cardiologist evaluation every 2-3 years with echo and ECG, Holter if concerns for tachycardia, baseline fasting lipid screen between ages 9-11, blood pressure assessment with routine health maintenance visits ○ Adulthood (>20 years): cardiologist evaluation with echo and ECG every 1-2 years, lipid panel every 3-5 years, blood pressure assessment with routine health maintenance visits, consider coronary computed tomography angiogram (CTA) for detection of early coronary artery disease, consider CTA or magnetic resonance angiogram if echocardiogram suggests aortic dilation
Neurology	<p><u>At risk for:</u> Macrocephaly, hydrocephalus, Chiari I malformation, syrinx, tethered cord, seizures</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Referral to Neurology with brain MRI; repeat within first 2 years of life, approximately 1 year later • MRI of lower spine for tethered cord (with one image of the entire spine for accurate count of vertebral bodies), once at diagnosis or by age 1 year <p><u>Ongoing management:</u></p> <ul style="list-style-type: none"> • Serial clinical exams with focus on walking, toe-walking, tendon reflexes, incontinence and other signs of progressive cord disease due to syrinx or tethered cord • Repeat imaging studies as needed
Neurocognitive Function	<p><u>At risk for:</u> Intellectual disability, speech and language impairment, orthopedic impairment, delayed/deficient fine- and gross-motor skills, impaired adaptive functioning</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Referral to early childhood services • Comprehensive speech and language evaluation, including oral-motor skills; therapy as indicated • Consider teaching sign language for speech/language and oral-motor deficits • Evaluation for augmentative or assistive communication, with training parents/caregivers • Occupational therapy and physical therapy assessment • Screening for autism spectrum disorder • For behavioral concerns: referral to a child psychologist for evaluation; applied behavior analysis (ABA) therapy as indicated • Evaluate and address possible parenting stress; screen for parent depressive

	<p>symptoms; refer to psychologist as needed</p> <ul style="list-style-type: none"> • Encourage reciprocal (“serve and return”) parent-child interactions • Advise parents on federal, state, and/or local resources for children with developmental delays/intellectual disability <p><u>Ongoing Management:</u></p> <ul style="list-style-type: none"> • Ongoing intervention and periodic re-evaluation by speech/language, occupational therapy, and physical therapy professionals • Neuropsychological evaluation at age 4 years or school entry, with re-evaluation prior to major transitions • Development of an Individualized Education Plan (IEP) upon school entry, for appropriate school programming (including possible Life Skills and/or special education instruction); extended school year; schooling until age 21 years as appropriate • Provision of related services at school including: speech/language therapy, OT/PT, Orientation & Mobility Services, Assistive or Augmentative Technology • If behavioral issues emerge in school, school should complete a functional behavioral analysis (FBA) to inform a behavior intervention plan (BIP) • Post high-school transition planning • For behavioral concerns: referral to a child psychologist for evaluation; ABA therapy; parent management training (PMT) • For social/emotional concerns: referral to a child psychologist for evaluation, with special attention to anxiety, especially at school entry; family behavior therapy/exposure therapy; PMT
Endocrinology	<p><u>At risk for:</u> Failure to thrive, short stature, growth hormone deficiency, hypoglycemia, delayed or precocious puberty</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Refer to endocrinologist <ul style="list-style-type: none"> ○ as newborn if hypoglycemia is an issue ○ between ages 2 and 3 years for growth monitoring • Obtain TSH, free T4, IGF-1 and IGF BP3 to screen for thyroid and GH deficiency • Nutritional assessment including 25-hydroxyvitamin D concentration and growth measurements <p><u>Ongoing Management:</u></p> <ul style="list-style-type: none"> • Monitor growth and refer to endocrinologist for significant acceleration or deceleration of height velocity • GH stimulation studies to be considered and directed by endocrinologist in all patients • Monitor for signs of precocious or delayed puberty • Replacement of vitamin D3 600 to 1000 units for patients with vitamin D deficiency (25 OH Vit D < 20 pg/ml)

Gastroenterology	<p><u>At risk for:</u> Failure to thrive due to feeding and/or swallowing difficulties, pyloric stenosis, gastroesophageal reflux, and increased resting metabolism, constipation</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Growth measurements (using syndrome specific growth charts, and general weight vs length charts to detect failure to thrive) • Refer to gastroenterologist for feeding difficulties, gastroesophageal reflux, failure to thrive, vomiting, and constipation • Nutrition assessment by dietician • For feeding difficulties: <ul style="list-style-type: none"> ○ Refer for feeding therapy ○ Refer to ENT specialist for evaluation of sucking and swallowing difficulties, consider swallow studies and FEES (flexible endoscopy), and evaluate risk for respiratory complications (i.e. aspiration pneumonia) • Evaluate for gastroesophageal reflux as recommended by gastroenterologist • If gastroesophageal reflux is present: <ul style="list-style-type: none"> ○ Consider conservative measures like dietary adjustments ○ Consider treatment with proton pump inhibitor or prokinetic drug ○ Consider feeding by nasogastric or gastrostomy tube ○ Consider fundoplication or jejunostomy • Evaluate for pyloric stenosis for vomiting at age 2 – 4 months <p><u>Ongoing Management:</u></p> <ul style="list-style-type: none"> • Regular follow-up to evaluate growth, weight, and nutrition • Assessment and treatment by dietician for failure to thrive or feeding difficulties • Feeding therapy for persistent feeding difficulties to stimulate oral feeding • Evaluate for late onset gastroesophageal reflux • Consider neurological complications (i.e. Chiari malformation) with progressive vomiting
Respiratory/ Otolaryngology	<p><u>At risk for:</u> Structural upper and lower airway anomalies, frequent infections, central and obstructive apnea, cardiopulmonary disease</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Evaluation for common airway issues. <p><u>Ongoing Management:</u></p> <ul style="list-style-type: none"> • Evaluation and treatment as needed • Sleep study in older individuals with symptoms suggestive of obstructive apnea
Dental	<p><u>At risk for:</u> Delayed tooth eruption, malocclusion, cross bite, bruxism and enamel erosion</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • A thorough dental evaluation with pediatric or general dentist <p><u>Ongoing Management:</u></p> <ul style="list-style-type: none"> • Appropriate regular dental hygiene

	<ul style="list-style-type: none"> • Consider additional fluoride to decrease caries • Restorative care • Orthodontic treatment as needed • Custom mouth guard may be considered to treat bruxism
Musculoskeletal	<p><u>At risk for:</u> vertical talus, pectus, hip dysplasia/subluxation, tight heel cords, shoulder and elbow contractures, ulnar deviation of the wrists, scoliosis, osteopenia/osteoporosis, and weakness</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Referral to pediatric orthopedist • Referral to physical therapist <p><u>Ongoing management:</u></p> <ul style="list-style-type: none"> • Monitor for scoliosis using Adam’s forward bend test at least annually • Radiographs depending on clinical findings (e.g. symptoms concerning for scoliosis, vertical talus, hip dysplasia) • Standard treatments by orthopedics/physical therapists based on clinical findings (e.g. bracing, surgery, orthotics) • Encourage strength training and physical activity • Dual energy x-ray absorptiometry in individuals with history of fracture • Magnetic resonance imaging of the entire spine for rapidly progressive scoliosis, new onset foot deformity, or prior to spinal surgical procedure
Genitourinary	<p><u>At risk for:</u> Cryptorchidism or labial anomalies, kidney malformation, vesicoureteral reflux, inguinal hernia, transitional cell carcinoma of the bladder beginning in adolescence</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Detailed physical exam • Renal ultrasound <p><u>Ongoing Management:</u></p> <ul style="list-style-type: none"> • Referral to urology and follow up with urology, as needed • Starting age 10 years, annual urinalysis for hematuria associated with bladder cancer
Ophthalmology	<p><u>At risk for:</u> Amblyopia, ptosis, nystagmus, refractive error, strabismus, optic nerve hypoplasia, optic atrophy, cortical visual impairment and delayed visual maturation, keratoconus</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Eye exam by pediatric ophthalmologist at birth or in early infancy • Intervention as appropriate <p><u>Ongoing management:</u></p> <ul style="list-style-type: none"> • Eye exam at 6 months and follow-up every 6 months for first 2 years • Supportive vision therapy and functional assessment by early intervention programs and vision resources for poor vision and abnormal depth perception • With optic nerve abnormalities, brain MRI to screen for malformations

Oncology	<p><u>At risk for:</u> Benign tumors, embryonal rhabdomyosarcoma, bladder carcinoma, neuroblastoma</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • If less than 10 years; abdominal and pelvic ultrasound <p><u>Ongoing Management:</u></p> <ul style="list-style-type: none"> • Repeat abdominal and pelvic ultrasound every 3 months until age 8- 10 • Annual urinalysis from age 10 years. Refer for evaluation for bladder carcinoma in cases of persisting hematuria • Investigation of unexplained symptoms for underlying malignancy
Dermatology	<p><u>At risk for:</u> Papillomas, palmoplantar keratoderma, acanthosis nigricans</p> <p><u>At diagnosis:</u></p> <ul style="list-style-type: none"> • Referral to pediatric dermatologist as needed <p><u>Ongoing management:</u></p> <ul style="list-style-type: none"> • Monitor for the development of papillomas. May be removed if symptomatic • Monitor for palmoplantar keratoderma, may need topical treatment • Recommend sun protection and precautions to avoid overheating
Adulthood	<p><u>Ongoing management:</u></p> <ul style="list-style-type: none"> • Cardiology follow-up, frequency dependent on previous diagnoses • Reflux symptoms assessment/management • Brain MRI if symptoms of Chiari I • Bone density monitoring • Regular dental cleanings—consider every 3 months rather than 6 months • Orthopedic treatment to maximize mobility and function • Regular eye/vision exams • Regular mental health assessment • Future care planning

Figure 1



Figure 2



Author Manuscript



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Gripp, KW; Morse, LA; Axelrad, M; Chatfield, KC; Chidekel, A; Dobyns, W; Doyle, D; Kerr, B; Lin, AE; Schwartz, DD; Sibbles, BJ; Siegel, D; Shankar, SP; Stevenson, DA; Thacker, MM; Weaver, KN; White, SM; Rauen, KA

Title:

Costello syndrome: Clinical phenotype, genotype, and management guidelines

Date:

2019-09-01

Citation:

Gripp, K. W., Morse, L. A., Axelrad, M., Chatfield, K. C., Chidekel, A., Dobyns, W., Doyle, D., Kerr, B., Lin, A. E., Schwartz, D. D., Sibbles, B. J., Siegel, D., Shankar, S. P., Stevenson, D. A., Thacker, M. M., Weaver, K. N., White, S. M. & Rauen, K. A. (2019). Costello syndrome: Clinical phenotype, genotype, and management guidelines. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 179 (9), pp.1725-1744.
<https://doi.org/10.1002/ajmg.a.61270>.

Persistent Link:

<http://hdl.handle.net/11343/286021>

File Description:

Accepted version